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ABSTRACT 
 
EFFECT OF ARTHROSCOPIC LAVAGE AND REPEATED THROUGH-AND-
THROUGH JOINT LAVAGE ON SYSTEMIC AND SYNOVIAL SERUM AMYLOID A 
CONCENTRATIONS; AS WELL AS TOTAL PROTEIN CONCENTRATION, 
NUCLEATED CELL COUNT AND PERCENTAGE OF NEUTROPHILS IN SYNOVIAL 
FLUID FROM HEALTHY EQUINE JOINTS 
 
Andrés F. Sánchez-Terán     Advisors:  
University of Saskatchewan, 2015    Dr. José L. Bracamonte 
        Dr. Luis M. Rubio-Martínez 
 
This research evaluated serum amyloid A (SAA) concentration in synovial fluid of 
healthy horses as a potential marker for use in the diagnosis and monitoring of horses with septic 
arthritis. The first study evaluated the effect of arthroscopic lavage of healthy joints on 
concentrations of systemic and synovial SAA; as well as total protein concentration, nucleated 
cell count and percentage of neutrophils in synovial fluid. The second study, evaluated the effect 
of repeated through-and-through joint lavage on SAA in systemic blood and SAA, total protein, 
nucleated cell count and percentage of neutrophils in synovial fluid from healthy joints. 
In the first study, middle carpal joints of 6 horses were randomly assigned to one of the 
following treatments 1) arthrocentesis (controls) or 2) arthroscopic lavage. A washout period of 
30 days was allowed in between treatments.  Synovial fluid and blood samples were collected at 
0, 24, 48, 72, 96 and 120 h. Measurements included SAA in blood and synovial fluid, and total 
protein, nucleated cell count and percentages of neutrophils in synovial fluid. 
In the second study, one tarsocrural joint was randomly assigned to receive repeated 
through-and-through joint lavage at 0, 48 and 96 h in 6 horses. Synovial fluid and blood samples 
were collected at 0, 24, 48, 72, 96 and 120 h. Measurements included SAA in blood and synovial 
fluid, and total protein, nucleated cell count and percentages of neutrophils in synovial fluid. For 
this study, synovial fluid samples collected at time 0 were considered as control values. 
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   After arthroscopic lavage and repeated through-and-through joint lavage, systemic and 
synovial SAA did not increase from baseline values (except for systemic SAA at 24h after 
arthroscopic lavage and in controls). Total protein values were significantly increased at all time 
points after arthroscopic and through-and-through joint lavages (except at 96h on both lavage 
procedures) but not in controls. With both lavage procedures, nucleated cell count significantly 
increased from baseline values at all time points (except at 96h after through-and-through joint 
lavage). Percentage of neutrophils was significantly increased after arthroscopic lavage at all 
time points and only at 24h in controls; however, the percentages of neutrophils were not 
significantly increased after repeated through-and-through joint lavage. 
Synovial SAA was not affected by arthroscopic or repeated through-and-through joint 
lavage; however, synovial total protein and nucleated cell counts were significantly increased. 
Synovial SAA may be a valuable inflammatory marker that is not affected by procedures as 
arthroscopic or repeated through-and-through joint lavage in horses. Further validation of 
synovial SAA as a marker for evaluating the progression of septic joints while treatment is 
installed is warranted. 
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CHAPTER 1: INTRODUCTION 
 
Septic synovitis is a severe disease that affects horses of all ages and can be life-
threatening. Over the last three decades, it has been a major topic of research because of the 
severe consequences it may have on affected horses. Accurate and prompt diagnosis followed by 
aggressive treatment increase the possibilities for survival and return to sporting activities.  
The main tools for diagnosing and monitoring treatment of synovial sepsis have typically 
been based on the use of inflammatory markers and bacterial culture from synovial fluid 
samples. Bacteria are not always isolated from synovial fluid or evident on cytology and 
consequently the specificity of these tests is low.11,24 Therefore, diagnosis and monitoring are 
based on clinical examination and analysis of synovial fluid. The common inflammatory markers 
analysed in synovial fluid include total protein concentration, nucleated cell count and the 
percentage of neutrophils. Although these inflammatory markers are widely used, they have 
shown limited accuracy as they can increase from any insult to the synovial structure, and not 
just from sepsis. 
Treatment of infection in a synovial structure is based on two major principles: 
eradication of infective organisms and rehabilitation of the synovial structure. The initial 
cleaning of the infected cavity is performed by active debridement and thorough lavage with 
sterile solution reducing the amount of bacteria as well as the inflammatory mediators present 
within the cavity. This is accompanied by the administration of systemic and regional 
antimicrobials to reduce further bacterial presence and multiplication within the joint. The 
preferred approach to lavage and debride the affected cavity is by the use of arthroscopy. 
Another option to provide lavage of a synovial structure is through needles placed on different 
pouches of the synovial cavity (through-and-through joint lavage). These procedures and the 
intra-synovial administration of antimicrobials increase the commonly used synovial 
inflammatory markers to values similar to those associated with synovial sepsis.78,79,94 Therefore, 
these inflammatory markers are not reliable especially after the joint has been treated; exposing 
the need to find new inflammatory markers that are not affected by the procedures used to 
resolve synovial sepsis. 
Serum amyloid A (SAA) in synovial fluid is an inflammatory marker that has promising 
characteristics as a more specific marker for sepsis. While SAA has been shown to increase in 
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synovial fluid to high concentrations during septic synovitis, its values were not modified by 
either arthrocentesis or intra-articular administration of amikacin.94 However, further evaluation 
of this marker after high volume fluid lavage by either arthroscopy or repeated through-and-
through joint lavage is needed before clinical use is recommended as a tool for monitoring 
treatment of synovial sepsis. If SAA concentration in synovial fluid is not modified after 
arthroscopic lavage or repeated through-and-through joint lavage in healthy horses, postoperative 
measurements of SAA in synovial fluid could be useful as a more specific marker for monitoring 
the response of treatment in septic synovitis. Advantages of validation of an specific marker for 
septic synovitis that is not affected by these therapeutic procedures not only will provide a 
prompt and accurate identification of treatment failure or success; but also might help in 
reducing hospitalization time, drugs administered, as well as serve as a prognostic indicator for 
survival or return to athletic performance. 
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1.1 Objectives and Hypotheses 
 
This work includes 2 studies: 
 
The first study was designed to evaluate the effect of arthroscopic lavage on systemic and 
synovial fluid SAA concentrations, as well as the effects on total protein concentration, 
nucleated cell count and percentage of neutrophils in synovial fluid in healthy equine middle 
carpal joints. It was hypothesized that: 
 
1) Total protein concentration, nucleated cell counts and percentage of neutrophils in 
synovial fluid would significantly increase after arthroscopic lavage. 
2) Systemic and synovial fluid SAA concentrations would not increase after arthroscopic 
lavage. 
 
The second study was designed to evaluate the effect of repeated through-and-through joint 
lavage on systemic and synovial fluid SAA concentrations, and total protein concentrations, 
nucleated cell count and percentage of neutrophils in synovial fluid in healthy equine tarsocrural 
joints. It was hypothesized that: 
 
1) Total protein concentration, nucleated cell counts and percentage of neutrophils in 
synovial fluid would significantly increase after repeated through-and-through joint 
lavage. 
2) Systemic and synovial fluid SAA concentrations would not increase after repeated 
through-and-through joint lavage. 
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CHAPTER 2: LITERATURE REVIEW  
 
2.1 Introduction 
 
 The understanding of septic synovitis as a common disease, how the synovial cavity 
reacts to infection, as well as the different treatment options and their effect on the common 
synovial inflammatory markers are exposed in the following literature review. Furthermore, 
SAA current research on its use as an inflammatory marker in horses as well as its recognized 
systemic and local (within the joint) functions are summarized to improve the understanding of 
this promising inflammatory marker for septic synovitis.  
 
2.2 Septic synovitis in the horse 
 
Septic synovitis is defined as a “purulent invasion of a synovial cavity by an infectious 
agent, which produces synovitis”.1 Infection of a synovial cavity is one of the most feared and 
severe diseases affecting horses of all ages. Clinical signs include synovial effusion, heat over 
the affected structure, and frequently is associated with severe lameness.2 Causes for horses 
acquiring infection of a synovial structure are varied and can be due to a penetrating wound,3,4 
hematogenous spread,5 and iatrogenic by intra-synovial injections or surgical intervention.6-8 The 
inflamed synovial cavity produces a strong inflammatory response to overcome the infection, 
which can produce damage to the cartilage leading to osteoarthritis. Treatment is prolonged and 
prognosis is not always favorable. It can be life-threatening as well as reduce the performance 
and future competitiveness of sport horses. Consequences include chronic pain, joint stiffness 
and contra-lateral limb laminitis amongst others.9,10 Research in the field of diagnosis and 
treatment of equine synovial infection has been quite extensive over the last decades.6 
 
2.2.1  Prognosis and factors associated with survival and return to previous performance 
 
Survival rates after septic synovitis vary according to the age group affected. Discharge 
rates from hospital after intensive treatment are lower in foals (45%) than in adult horses (85%) 
due to concurrent conditions such as osteomyelitis, multiple joint involvement, 
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hypogammaglobulinaemia and multisystemic disease.4,11-13 Survival rates for horses having 
septic tenosynovitis have also been reported where 91% of treated horses survived to discharge.  
The future career of horses affected by synovial sepsis has also been investigated and 
varies with age and whether infection is present in a joint or a tendon sheath. Only 48% of 
Thoroughbred foals that survived to discharge (45%) after being treated for septic arthritis 
started in at least one race in their career, which is less than the average of 66.2% of healthy foals 
that race.14 Considering only adult horses being discharged from hospital, 56% to 81% of these 
horses were able to return to racing after synovial sepsis.2,4,11 In another report, 11 of 12 horses 
returned to their previous level of performance.8 Furthermore, only 69% of the horses surviving 
to discharge after septic tenosynovitis, returned to their previous athletic use.15,16 However, 
another study reported a lower rate of 56% of horses with septic tenosynovitis returning to 
previous use.17  
Different factors have been reported to be associated with survival. These include time 
from injury to treatment,16,18,19 positive bacterial cultures,2 presence of bone or tendon 
pathology,4,12,16,18,20 identification of inflammatory pannus4,18,19 or osteochondral fragments,18 
elevated nucleated cell count (NCC),12,21 increased matrix metalloproteinases (MMPs)21 and total 
protein,19 timing of general anesthesia and total number of surgeries performed.19 Also, 
iatrogenic infection after intra-articular injection with corticosteroids has been associated with 
poor prognosis.8 
Early recognition and aggressive treatment of synovial sepsis has been associated with 
better prognosis for survival and return to athletic function than when treatment is delayed in 
adult horses.6,9 Horses treated within the first 24 h after contamination of a synovial structure 
(open joint injury) were less likely to develop infectious arthritis and more likely to return to 
normal performance than horses treated after 24 h.22 In a recent study on septic tarsocrural joints, 
early treatment resulted in complete recovery, while chronic cases had prolonged recovery 
without achieving soundness.20 However, in some cases, aggressive treatment after several days 
from the initial joint contamination can also lead to satisfactory outcomes with horses returning 
to previous athletic function.2,4,8,12,14,15,19,21,23 Contradictory results have been also reported in 
regards to septic tenosynovitis. Three studies suggest that the time gap between injury and 
appropriate treatment had no impact in the outcome and might not be useful for formulating a 
prognosis.11,15,17 However, one study found that treatment initiated within 36 h after injury 
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carried a better prognosis for returning to athletic performance (89%) than when treatment was 
initiated after 36 h (40%).16 Furthermore, a study found horses being treated within 12 h after 
injury had a worse prognosis maybe due to the severity of the initial wound which was noticed 
sooner by owners and warranted immediate attention and euthanasia.16  
 Although bacteria are present during synovial sepsis, they are difficult to isolate11,24 and 
the absence of a positive bacterial culture does not indicate absence of synovial sepsis.24,25 One 
study reported that a positive culture had no effect on the likelihood of horses surviving to 
hospital discharge.11 On the other hand, successful isolation of bacteria from an infected synovial 
structure was associated with a poorer prognosis for survival in a different study.2 In the latter, 
only 74.6% of horses with synovial sepsis that yielded a positive culture survived to hospital 
discharge compared to 97.1% survival of horses with synovial sepsis that did not yield a positive 
culture.2 In addition, culture of Staphylococcus aureus had a negative effect on long-term 
outcome8 and these horses were 29.5 times more likely to be euthanized than horses that yield a 
negative culture.2 Horses that survived after S. aureus synovial infection had a reduced 
likelihood of returning to previous level of performance (30.8%).2 In addition, horses that 
yielded another bacterial genus different from S. aureus were only 13.9 times more likely to be 
euthanized than horses that yielded a negative culture.2 
  The presence of tendon or bone involvement has also been associated with decreased 
survival and reduced athletic outcome.12 Horses with septic tarsocrural joints with radiographic 
subchondral bone lysis and osteophyte formation were found to have longer convalescence and 
lower percentage returned to athletic activity compared to horses without radiographic 
abnormalities.20 Bone or tendon pathology are not always noticed on initial assessment and 
repeated examinations during treatment are indicated in refractory cases.12  
 
2.2.2  Causes of septic synovitis and common bacterial isolates 
 
 Causes for developing synovial sepsis vary with age of patient. Foals are more prompt to 
acquire septic arthritis during septicemia while in adult horses wounds are the most common 
cause for septic synovitis.2,20 Often, several joints are involved in foals and Gram-negative 
bacteria generally are the cause of septic polyarthritis and osteomyelitis.11,26 Obtaining positive 
bacterial cultures in foals with septic arthritis diagnosed based on cytological results, is 
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challenging and two studies have reported that only 32.5%11 and 11%26 of samples yielded a 
positive culture. Septic synovitis after a wound is commonly associated with the introduction of 
microorganisms along with foreign material, 2,20 exacerbating the infection.11,17,18 After a wound 
involving a synovial structure, only 32.9% of synovial samples yielded a positive bacterial 
culture.2 The synovial structure most commonly infected after a wound is the tarsocrural joint 
(22.4%) followed by the metacarpal/metatarsal-phalangeal joints (20.1%) and the digital flexor 
tendon sheath (18.7%).2  
Commonly isolated microorganisms during septic synovitis include aerobes or facultative 
anaerobes. The most commonly cultured genus of bacteria is Enterobacteriaceae followed by 
Streptococcus spp. and Staphylococcus spp.27 A variety of bacteria can be expected in cases of 
perforating wounds, while Staphylococcus spp. is more commonly isolated in infections after 
surgical intervention.8,11 When a cause for synovial sepsis in adult horses cannot be identified, it 
is defined as idiopathic synovitis. This entity is thought to have a hematogenous origin and 
Gram-positive bacteria are usually identified.11 
Iatrogenic contamination can occur after intrasynovial injection and after a surgical 
procedure involving a synovial structure.2,7 Sepsis following synoviocentesis and surgery is 
commonly related to Staphylococcus aureus. However other bacteria like Streptococcus spp., 
Enterobacteriaceae, Pseudomonas spp. and Klebsiella spp. have been isolated.3,8,11 In a recent 
study, only 0.5% of joints developed septic arthritis as a complication after elective arthroscopy 
without perioperative antimicrobial therapy.7 In a large retrospective study where 2833 medical 
records were reviewed from horses receiving intra-articular injections without prophylactic 
antimicrobials, it was found that the incidences of septic arthritis after an intra-articular injection 
with any substance was 0.092%, after local anesthetic 0.091%, corticosteroids 0.161%, 
hyaluronan 0.159%, and after polysulfated glycosaminoglycan injection 0.394%.28 Although 
controversial, the authors of the latter study concluded that infectious arthritis following intra-
articular injection is rare and the use of prophylactic antimicrobials might be unnecessary.28 
 
2.2.3  Inflammatory response of the synovial structure to bacteria 
 
Factors associated to whether or not a synovial structure can resist an inoculation of 
microorganisms are organism-related (pathogenicity, virulence and number of organisms);11 
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immunological status of the animal;5 and the presence of foreign material.29 In neonates, a 
complete or partial failure of passive transfer of immunoglobins is the most common underlying 
cause that predispose to the development of bacteremia as a complication of umbilical infection, 
pneumonia or diarrhea.14,30,31 The bacteria may settle in joints and their adjacent tissues in foals 
younger than 6 months of age, most likely because of the low oxygen tension associated with 
local low blood flow.31  
The articular inflammatory response to infection is mediated by the innate immune 
system directed towards the elimination of the microorganism and the repair of damaged tissue.32 
Healthy synovial structures are able to control synovial contamination with a certain amount of 
bacteria and impede their proliferation.9 In an in vitro study, 10g of normal equine synovial 
membrane were capable of neutralizing 100 colony-forming units of Staphylococcus aureus.33 
When infection and proliferation of bacteria occur, the joint usually produces a marked 
inflammatory response, which is determined by factors such as host immunity, number of 
inoculated bacteria and bacterial virulence.9 The degree of tissue damage by the inflammatory 
response varies according to the host age, host debilitation, duration of infection, bacterial 
virulence and pre-existent joint disease.9 
The local inflammatory response is initiated by the release of pro-inflammatory 
molecules by the injured tissue. These molecules include reactive oxygen species (O2-, OH, NO, 
and H2O2), arachidonic acid metabolites and modified host proteins, which induce the migration 
and activation of cells such as neutrophils and macrophages, as well as the production of large 
protective molecules such as complement components and antibodies.32 Different cells including 
synoviocytes and neutrophils respond to the stimulus by synthetizing and releasing cytokines, 
which include TNF-α, IL-1, IL-6; as well as free oxygen radicals, and destructive enzymes 
(lysozyme, elastase, cathepsin G, gelatinase, caseinase, and collagenase).34,35 All of these 
products contribute to the disruption of the blood-synovial barrier. This facilitates the access of 
many nonspecific mediators, which amplify the inflammatory cascade by further activating the 
synoviocytes.9 Total protein content in the synovial fluid also increases because of the increased 
capillary permeability, which allows high molecular weight proteins (mainly globulins) to enter 
the joint.36 Chondrocytes activated by IL-1, TNF-α and free radicals35 release MMPs 
(stromelysin, collagenase, gelatinase) which decrease proteglycan synthesis.35 These MMPs are 
responsible for the cartilage breakdown leading to the development of osteoarthritis.10  
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If the amount of inflammatory molecules released by the injured tissue is high, a systemic 
reaction may be induced, leading to an acute phase response (APR).32 The APR is composed of a 
serial of local and systemic changes that involve many cell types and organs.37 Several proteins 
called acute phase proteins (APPs) are released into the systemic circulation during an APR.32 
The APPs are produced mainly by the hepatocytes after being stimulated by IL-1, TNF-α, 
and especially IL-6.32 Their synthesis and release usually begins a few hours after injury.32 The 
APPs include complement components, clotting molecules, protease inhibitors, and metal-
binding proteins.32 The majorly investigated APPs include SAA, C-reactive protein (CRP) and 
haptoglobin, as well as α1-acid glycoprotein. In humans, CRP and SAA are the major APPs,38 
but in horses CRP has a limited and later response to stimuli and because of this, is not 
considered a major APP.39 The major APPs have very low or undetectable plasma levels in 
healthy animals and their concentrations can rise more than 100-1000 times during APR.40  
 Macroscopic changes within the synovial cavity vary depending on chronicity of the 
infection. The major finding during acute infection is severe synovitis.41 When osteochondral 
defects are not present, chronic septic arthritis is characterized by cartilage degeneration. In 
contrast, if there is a defect in the subchondral bone this may result in infected 
osteitis/osteomyelitis.41 During chronic tenosynovitis, when the epitenon is intact, synovial 
proliferation and adhesion formations are the major findings. On the other hand, if the epitenon 
is affected, there is usually rapid intra-tendinous collagenolysis.41 Intra-synovial fibrinocellular 
conglomerate (pannus) is usually seen in established infections.41 Pannus commonly develops 
over areas of villous synovium, and villi may be completely covered.41 It can then cover avillous 
synovium and, in advanced cases, articular cartilage or tendon surfaces may be also covered. 
Pannus may hide foreign material and devitalized tissue; as well as be rich in inflammatory cells, 
degradative enzymes and radicals.41 In addition, it can also act as a region for bacterial 
multiplication and as a barrier for synovial diffusion, limiting synovial nutrition and access for 
circulating antimicrobial drugs.41  
 
2.2.4  Diagnosis and monitoring of septic synovitis 
 
The common clinical signs seen in a horse with septic synovitis include heat over the 
affected structure, synovial effusion and severe lameness.2 An increase in body temperature 
	   10	  
might be seen in some cases, but is not a common finding.42 Horses usually present with a 
lameness grade of 4 to 5 out of 5.20,43,44 There is increased joint effusion with accompanying 
increased digital pulses in infection of synovial cavities in the distal limb (proximal and distal 
interphalangeal joints, carpometacarpal/tarsal joints as well as digital flexor tendon sheath and 
navicular bursa).43 The administration of intra-synovial local anesthetic does not always 
alleviates lameness.43  
Radiographic assessment of septic synovial structures is recommended.20,43 It may reveal 
increased width of the joint space, soft tissue swelling, subchondral bone lysis and 
osteophytosis.20,43 In some cases radiographic changes are evident early in the course of sepsis; 
however, there is frequently a time lag from injury to evidence of radiographic changes.42 
Consequently, if there is no radiographic evidence of osteomyelitis before initiating treatment, it 
is recommended that radiographs be repeated in refractory cases.31 
 Bacteria are not always cultured from septic synovial samples11,24 and this is not 
necessarily associated with parenteral administration of antimicrobials before synoviocentesis.2,45 
Sequestration of the bacteria into the synovial membrane3 and the bactericidal effect of synovial 
fluid46,47 may be reasons for obtaining a negative culture. Other factors that may contribute to a 
negative culture are sample handling (samples should be processed within 1 h after collection48), 
low number of organisms present and low virulence of organisms.31,48 Reported success rates in 
obtaining a positive culture from septic synovial fluid range from 22% to 79%.2,11,24,43,48,49 
Synovial fluid samples are recommended to be placed into a bacterial culture bottle to maximize 
the likelihood in obtaining a positive result.31 The use of blood culture bottles50 and enrichment 
broth prior to culture2 have been reported to be advantageous48. Other studies have reported that 
culture enhancement techniques with blood culture media allow for bacterial isolation in 87% to 
100% of septic joints.51,52 
 In conjunction with clinical signs and bacterial culture, diagnosis of synovial sepsis is 
facilitated by the use of synovial fluid analysis.2 Total protein concentration and total nucleated 
cell count are measured in synovial fluid.53 Cytology of the synovial fluid precipitate is 
commonly advantageous for obtaining an accurate diagnosis.53 The use of Gram stain of synovial 
fluid can sometimes expose bacteria and confirm sepsis.53 In addition, the percentage of 
neutrophils obtained during cytology can help in diagnosis synovial sepsis.53 Degenerative 
neutrophils are not commonly encountered, but when found are highly suspicious of sepsis.11,24,53 
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The reference values for normal synovial fluid have been documented as total protein 
<25 g/L, nucleated cell count <1 x 109 cells/L and percentage of neutrophils being <10%.54,55 
Sepsis has typically been considered when synovial fluid yields a total protein ≥40 g/L, 
nucleated cell count ≥30 x 109 cells/L and percentage of neutrophils ≥80%.53,54 However, other 
authors have suggested synovial sepsis with values of nucleated cell counts ≥ 5 x 109 
cells/L4,8,11,19 and total protein >30 g/L.2 The latter ranges can be found during non-septic 
synovitis and should be used with caution and together with clinical signs of septic synovitis.53 
 Few studies have focused on assessing and monitoring treatment for septic synovitis. A 
subjective grading system has been developed in human medicine to predict the efficacy of 
treatment based on radiographic findings and findings during exploratory arthroscopy.56 In a 
retrospective study investigating prognostic indicators for adult horses with synovial sepsis, 
synovial fluid samples obtained 4 to 6 days after initiating surgical treatment for septic arthritis 
were classified as ‘unremarkable’ (NCC ≤1 x 109 cells/L, and neutrophils ≤30%), ‘synovitis’ 
(NCC >1 to <5 x 109 cells/L, or neutrophils >30% to <80%), and ‘sepsis’ (NCC ≥5 x 109 cells/L, 
or neutrophils ≥80%).12 It was found that horses classified at 4 to 6 days postsurgical as 
‘synovitis’ and ‘sepsis’ had a reduced percentage of survival to discharge (84%) and return to 
athletic function (47%) than horses classified as ‘unremarkable’ (100% and 90%, respectively). 
In the same study it was suggested that concerns regarding iatrogenic exacerbation of 
inflammation by surgical manipulation might be unfounded as 39% of the horses in the study 
returned to normal values rapidly after surgery and were classified as ‘unremarkable’ at 4 to 6 
days. In another retrospective study that investigated factors associated with survival to hospital 
discharge after endoscopic treatment for synovial sepsis in horses, a total protein concentration 
of 50-55 g/L obtained after arthroscopic lavage was associated with reduce likelihood of survival 
to hospital discharge.19 Also, persistent synovial infection during treatment demonstrated by a 
positive bacterial culture have shown to be associated with a reduced prognosis for survival.2 
 
2.3 Treatment options for septic synovitis and their effects on common synovial 
inflammatory markers 
  
When treating synovial infection removal of debris, foreign material, devitalized and 
contaminated tissue, as well as destructive enzymes and radicals should be achieved by some 
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form of drainage or lavage.41,57,58 Closed suction drainage is advantageous as it is thought to 
remove damaging waste products continuously and maintains patient comfort by avoiding 
increased joint effusion.23 A method suggested for early cases of septic synovitis is ‘distention-
irrigation’ in which a large-gauge needle is inserted into the synovial cavity and infusion and 
aspiration of an irrigating fluid is done.58 As an alternative to the latter method, through-and-
through joint lavage is used and allows for a continuous flow of an irrigation fluid.58 On well 
established infections fibrin clots can be too large to be flushed by through-and-through joint 
lavage57 and arthrotomy or arthroscopy are necessary to treat these cases successfully.58 
Arthrotomy allows extensive lavage and drainage by leaving the surgical incisions open.59,60 
However, arthrotomy complications include premature healing of the arthrotomy site or, in 
contrast delayed healing.61 In acute infections, arthroscopy, synovectomy, and lavage are 
preferred over arthrotomy and lavage.23,61 Arthrotomy and lavage eliminated infection more 
effectively and provided better drainage than arthroscopy, synovectomy and lavage during 
experimentally induced Staphylococcus aureus infection to the tarsocrural joint.61 However, 
joints that were treated by arthrotomy had a greater rate of ascending bacterial contamination.61 
Therefore, arthroscopy with synovectomy and lavage is preferred in cases of septic 
arthritis.15,23,61  
Variations of these techniques have also been described and include arthrotomy followed 
by insertion of closed suction3 or open passive drains,62 open drainage59,61,63 and arthroscopy 
followed by closed suction drainage,8,23 fenestrated drains,17 multi-fenestrated indwelling lavage 
systems,64 or creation of an open draining wound.9 In chronically infected joints, and where 
amenable, ankylosis can be performed if the joint function is irreversibly compromised.43,65 In 
chronic cases of sepsis of the common digital extensor sheath, complete surgical resection of the 
affected tendon and ablation of the tendon sheath has been successfully performed obtaining 
good prognosis for return to soundness.66  
Although its use is not common and still controversial, dimethylsulfoxide (DMSO) has 
been used to treat septic arthritis successfully.43 It has been proposed that DMSO binds and 
neutralizes oxygen-derived free radicals and suppresses prostaglandin production and therefore 
reduces further cartilage degradation and decreases inflammation.43,67 
 Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used to alleviate 
lameness by controlling pain and inflammation68 and as an analgesic administered peri-
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operatively.69 Phenylbutazone and flunixin-meglumine are commonly used.6 These are non-
selective cyclooxygenase (COX) inhibitors and can cause renal and gastrointestinal toxicity.70,71 
The risk of toxicity associated with non-selective COX inhibitors can increase when dehydration 
is present, therefore this should be monitored when phenylbutazone and flunixin-meglumine are 
administered.6,71 Recently firocoxib (an specific inhibitor of COX-2 isoenzyme72) has been used 
when long-term administration of NSAIDs is needed.73,74 The use of firocoxib was associated 
with low risk of developing NSAIDs toxicity in horses73 and proved to have similar effects in 
reduction of lameness as phenylbutazone.74 Intra-articular corticosteroids60 may be used after 
sepsis has resolved, as well as hyaluronic acid75,76 and polysulphated glycosaminoglycans76 to 
restore the joint environment and prevent or treat further degenerative joint disease. 
 Strict stall rest has been advised during the acute phases of inflammation and heavy 
bandages can be placed if necessary.58,60 Bandages can serve to reduce and control swelling by 
providing compression.6 If wound care and local therapy are needed daily, bandages are usually 
changed on a daily basis to allow treatment until synovial infection resolves and wounds are 
healed.6 It has also been recommended that after resolution of infection, the patient should be 
confined for several weeks and reintroduced to exercise slowly.58 Controlled exercise with the 
addition of physical therapy that may include passive range-of-motion exercises, can be 
performed once infection and synovitis have resolved.6 
 
2.3.1  Arthroscopic lavage 
 
Arthroscopy is the preferred procedure to lavage joints when sepsis is present. It is a 
minimally invasive procedure which allows good visualization of the joint structures, access to 
remote parts of the joint, as well as removal of fibrin, debridement of infected bone and 
synovectomy.23,41,61 The infected synovial cavity can be assessed for concurrent damage to 
cartilaginous, osseous and soft tissue structures to determine prognosis.4,18,56 Arthroscopy also 
allows lavage with high volumes facilitating removal of inflammatory mediators from the 
infected synovial cavity.77 
The inflammatory response of gas or fluid distention during arthroscopy in healthy 
equine joints has been reported.78 Tarsocrural joints were distended with warm carbon dioxide 
(CO2) gas or lactated Ringer’s solution (LRS) both at set pressures of 24 mmHg for 30 
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minutes.78 Synovial fluid samples were then collected at 0, 6, 12, 24 and 48 h after the procedure. 
At 6 h, all samples from both gas and LRS distention were cloudy and red in color. Samples 
obtained from gas distended joints acquired an orange color which improved over time in 
contrast to LRS distended joints that remained red in color until the end of the study (48 h). 
Values of nucleated cell counts were similar between groups reaching values as high as 20 to 25 
x 109 cells/L at 6 and 12 h after arthroscopy and then slowly decreasing in values. However, they 
were still significantly different to baseline values (time 0 h) at 48 h. The percentage of 
neutrophils were >80% at 6 and 12 h and slowly decreased to values ~60% by 48 h. The total 
protein concentration was also similar in both groups and reached its peak at 24 h after the 
procedures (specific values not reported). The only significant differences reported between 
groups were the levels of hemoglobin and leukocyte oxidative burst, which were lower in the gas 
distended group than in the LRS distended group. This indicates that CO2 arthroscopy produced 
less intra-articular bleeding and activation of infiltrating leukocytes than LRS distention. 
 Another study evaluated the changes in synovial fluid after arthroscopic partial 
synovectomy in horses.79 Lavage of the middle carpal joints was performed with 7.2 L of LRS at 
a rate of 110 mL/minute and synovectomy was performed on one limb and the contralateral 
received only arthroscopic lavage with the same amount of LRS. Synovial fluid samples were 
collected before arthroscopy and 14, 21 and 28 days after arthroscopy. Because sampling was not 
done immediately after the procedure, the acute inflammatory response of the joint to 
arthroscopy lavage and arthroscopic partial synovectomy was missed in this study. Samples in 
both groups were turbid or slightly hemorrhagic for 4 weeks and samples at 21 and 28 days were 
clearer than those obtained at 8 and 14 days. At 8 days after arthroscopic lavage and after 
arthroscopic lavage and synovectomy, total protein (27.6 ± 6.5 g/L and 29.8 ± 4.1 g/L 
respectively), nucleated cell counts (0.81 ± 0.57 x 109 cells/L and 1.21 ± 1.07 x 109 cells/L 
respectively) and percentage of neutrophils (33 ± 25%) were significantly increased from 
preoperative values. By the end of the study (28 days), synovial fluid parameters were still 
significantly higher than baseline values in some horses.  
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2.3.2  Through-and-through joint lavage 
 
Lavage of a synovial structure by placing at least two needles and performing a through-
and-through joint lavage has been shown to be effective in treating septic arthritis.43,57,60 In 
chronic cases, where pannus and fibrin are present, it has been recommended to place several 
needles in different synovial pouches to obtain a more thorough lavage of the entire synovial 
cavity.43 The mean number of through-and-through joint lavages required to resolve synovial 
sepsis in a clinical study was 3 (range 2-15).57 However, in this study, clinical cases were only 
treated with joint lavages and systemic antimicrobials; antimicrobials were not administered 
regionally. 
 The effect of through-and-through joint lavage with four antiseptic solutions was 
evaluated in healthy equine tarsocrural joints.80 Three concentrations of povidone-iodine (0.1%, 
0.2%, and 0.5%) and one concentration of chlorhexidine (0.5%) were compared. Both 0.5% 
povidone-iodine and 0.5% chlorhexidine induced severe lameness, soreness at palpation and 
limb enlargement. Results from this study concluded that 0.1% povidone iodine in balance 
electrolyte solution is the only bactericidal joint lavage solution recommended in the horse. The 
other solutions produced synovitis of different degrees and particularly 0.5% chlorhexidine 
produced a significant increase in nucleated cell counts, percentage of neutrophils and cartilage 
damage visible on histopathology.  Balanced electrolyte solution was used as a control solution 
and induced synovitis at 24 h after lavage with nucleated cell counts reaching up to 38 x 109 
cells/L, total protein reaching up to 5.3 g/L and approximately 80% of neutrophils (non-
degenerative). In another experimental study, 0.1% povidone-iodine was used in joints 
experimentally infected with Staphylococcus aureus to evaluate its efficacy as bactericidal 
compared to balanced electrolyte solution.81 It was concluded from this study that through-and-
through joint lavage with 0.1% povidine-iodine had no advantage over lavage with balanced 
electrolyte solution for the treatment of infectious arthritis in the horse. 
  Chlorhedixine at a concentration of 0.05% was evaluated as a single lavage solution in 
healthy tarsocrural joints resulting in synovial ulceration, inflammation and abundant fibrin 
accumulation.82 Therefore, it was not recommended for use in equine joints. In the same study, 
through-and-through joint lavage with LRS was used as control. Total protein in control joints 
was not affected by LRS lavage, but nucleated cell counts and percentage of neutrophils were 
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significantly increased at 24 h after lavage with LRS (up to 8.3 x 109 cells/L and up to 71%; 
respectively). Later on, the effect of through-and-through joint lavage with potentiated 
chlorhexidine solution (0.0005% chlorhexidine in EDTA-Tris) was evaluated in healthy 
tarsocrural joints of horses.83 It was found that potentiated chlorhexidine had no detrimental 
effects to synovium or articular cartilage but produced synovitis that resolved at 8 days post-
lavage. In the same study, phosphate-buffered saline solution was used as control lavage solution 
and had similar effects as potentiated chlorhexidine producing a synovitis characterized by 
increased nucleated cell count (25.7 x 109 cells/L ± 28), total protein (3.0 g/L ±0.6) and 
percentage of neutrophils (68.7% ± not reported). 
 
2.3.3  Antimicrobial administration 
 
Systemic antimicrobials have been recommended when treating synovial sepsis for an 
extended period of at least 3 weeks.17,42 When synovial sepsis is suspected, broad-spectrum 
antibiotics are given systemically until results of bacterial culture and bacterial antimicrobial 
sensitivity are available.6 The antimicrobials given initially are chosen based on the suspected 
cause for the synovial infection (e.g. iatrogenic infection or by a wound).6 To obtain a good 
broad-spectrum coverage, antimicrobials with Gram-positive (e.g. β-lactam or a cephalosporin) 
and Gram-negative (e.g. aminoglycosides or fluorquinolones) spectrum should be combined.6 
When iatrogenic infection is suspected, aminoglycosides are commonly chosen and particularly 
amikacin has shown to be highly effective against 95% of bacteria isolated from horses with 
postoperative septic arthritis including Staphylococcus spp., Enterobacteriaceae and 
Pseudomonas spp.84 If infection with an anaerobic bacteria is suspected (e.g. Bacteroides) the 
antimicrobial selection should include metronidazole.6 If a positive bacterial culture is available, 
systemic antimicrobial therapy should be based on bacterial sensitivity results.6  
Bacterial resistance to antimicrobials is a challenging clinical scenario in human and 
veterinary medicine.6,85 Methicillin-resistant Staphylococcus aureus (MRSA) is usually a 
nosocomial infection and can be zooanthroponotic (reverse zoonotic disease).85 Unfortunately in 
equine medicine a variety of antimicrobial drugs against MRSA are not available.6 In horses, 
imipenem and vancomycin have been used successfully to treat orthopedic MRSA infections86 In 
humans, resistant infections can be treated with different antimicrobials like oxazolidinone, 
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linezolid, pristinamycin, ortavancin, dalbavancin, romaplanin, tigecycline, BAY73-7388 and a 
newer antimicrobial named daptomycin.6  
Systemic antimicrobials are commonly combined with local administration of 
antimicrobials either by intra-synovial injections59 or by regional limb perfusion when treating 
synovial sepsis.87 Intra-synovial administration of antimicrobials achieves an immediate synovial 
concentration of the antimicrobial above the MIC for common bacterial equine isolates.88-90 Low 
quantities of antimicrobial are needed to obtain high concentrations.88-90 However, intra-articular 
injections of antimicrobials have shown to produce a mild transient inflammatory reaction that 
usually resolves without further treatment.88-90  
Various antimicrobials have been shown to be safe for intra-synovial 
administration.3,84,88,89 Ceftiofur can be safely administered intra-articularly in horses and it is 
commonly used based on bacterial sensitivity.88 Aminoglycosides have become the preferred 
intra-articular antimicrobial drugs for the prevention and treatment of equine joint sepsis.84 Intra-
articular administration of gentamicin achieves concentrations in synovial fluid above the MIC 
for many common equine bacterial isolates for more than 24 h.89 Gentamicin administered intra-
articular at a dose of 150mg results in a higher concentration (about 1000-fold) than when given 
systemically.89 Gram-negative bacteria can be resistant to gentamicin and this has reduced its 
use, however it is still effective against Staphylococcus spp. and Streptococcus spp.91 In the other 
hand, amikacin has poor activity against Streptococcus spp. but is more effective than 
gentamicin against Staphylococcus spp. and Gram-negative bacteria.91 Intra-articular 
administration of 250 to 500 mg of amikacin sulphate every 24 or 48 h is commonly used for the 
treatment of septic arthritis.3 A single administration of 500 mg of amikacin into the radiocarpal 
joint of horses produced synovial concentrations of amikacin that remained above the reported 
MIC for most equine pathogens for 72 and 48 h in normal and inflamed joints, respectively.90,92 
Amikacin produced toxic effects on equine chondrocytes in explant cultures.93  
Repeated intra-synovial administration of antimicrobials is most commonly performed 
via arthrocentesis every 24 to 48 h when treating septic arthritis in horses.3 Repeated intra-
articular administration of amikacin significantly increased total protein (43.2 ± 9.5) and 
nucleated cell counts (2.49 ± 2.48 x 109 cells/L), and total protein values were higher than the 
reference values for septic arthritis in some horses.94  
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Antimicrobial drugs can also be safely delivered by intra-synovial constant rate infusions 
systems.95-97 The advantage of using intra-synovial constant rate systems for infusion of 
antimicrobials when treating septic synovitis include avoiding daily synoviocentesis6 as well as 
lavage of the joint by the same system.87,97,98 Gentamicin has proved to be safe to deliver by 
intra-synovial constant rate infusions obtaining high concentrations above the MIC for most 
equine bacterial isolates96 not only in synovial fluid, but also in associated synovial structures 
(subchondral bone synovial membrane, and joint capsule).95 Other antimicrobials that have been 
used by an intra-synovial constant rate system are amikacin and ticarcillin with clavulanate 
obtaining up to 92% of horses that recovered successfully from septic synovitis.97 
Intra-articular antimicrobial-impregnated beads are used in chronic cases of synovial 
sepsis where osteomyelitis is present.99,100 In one report, where all cases were refractory to 
standard treatments, antimicrobial-impregnated beads were used and left for 14 days intra-
synovially.100 In this report, 11 out of 12 horses recovered successfully and returned to previous 
athletic function. 
 Regional limb perfusion with antimicrobial drugs has been shown to achieve high and 
prolonged levels of the drug in synovial fluid101 and to eliminate infection successfully.87,102 The 
use of regional limb perfusion has lead to similar rates of survival to discharge and return to 
previous performance than with other techniques used for regional delivery of antimicrobials.87 
Regional limb perfusion can be performed either by intra-osseous regional limb perfusion 
(IORLP)101 or by intra-venous regional limb perfusion (IVRLP).103 Both techniques are widely 
used, however IVRLP can have fewer complications than IORLP87 and therefore is preferred.87 
With IVRLP, high concentrations of antibiotics are obtained in bone tissue and this might 
increase the success in treating synovial sepsis with concurrent osteomyelitis.87 
 
2.4 Biology of serum amyloid A 
 
Serum amyloid A is a characteristic and sensitive acute phase protein in several animal 
species and humans.104 Serum amyloid A is an apolipoprotein and the majority of SAA circulates 
in plasma bound to the fraction 3 of high-density lipoprotein (HDL3) and a minority circulates in 
a free form.105,106 It is primarily synthesized by the liver, but it is also expressed in several other 
tissues which will be discussed in the following sections of this literature review.107 During acute 
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inflammation approximately 2% of the total hepatic protein synthetic capacity is dedicated to 
produce SAA.108 Serum amyloid A induction is mediated by IL-1, IL-6 and TNFα; as well as 
other cytokines produced by activated macrophages.109 It undergoes hepatic degradation110 and 
has a short plasma half-life of 75 to 80 minutes.111 Serum amyloid A has been associated with 
amyloidosis in humans and horses and this disease has been classified according to the protein 
that makes the majority of the deposits (for deposits of SAA is AA amyloidosis); and according 
to whether the disease is primary (originates from a disorder in the immune cell function) or 
secondary (originates during chronic inflammatory diseases).112 During chronic inflammatory 
disease such as rheumatoid arthritis in humans, SAA is persistently increased and has an 
important role in the development of AA amyloidosis, which is a type of amyloidosis described 
as an abnormal deposition of SAA in the extracellular space of several organs.113 Serum amyloid 
A is the precursor for amyloid protein AA that is the main fibril protein in secondary (reactive) 
amyloidosis in humans.113 In horses, reactive amyloidosis has been induced after repeated 
stimulation by microbial agents for the production of antibodies and the complete amino acid 
sequence of protein AA has been reported by this procedure.114 Also, in humans, SAA has been 
well correlated with the risk of developing cardiovascular disease and this suggests SAA has a 
role in the pathogenesis of arteriosclerosis.115,116 The functions of SAA are poorly understood 
and it has been suggested that SAA may serve as a local defense mechanism against 
inflammatory stimuli during the time lapse between the stimuli and the mounting of a systemic 
(hepatic) inflammatory response.117 
 
2.4.1  Molecular architecture, genes expression and isoforms  
 
Equine SAA is a 9-11 kilodalton, hydrophobic,118 apolipoprotein.105,119 The primary 
structure of SAA consists of 110 amino acid residues with microheterogeneities found on 
positions 16, 44, and 59.114 This demonstrates the existence of more than one SAA gene in the 
horse.118 There is a marked homology within human SAA and SAA in other several animal 
species, showing that SAA is a well-conserved protein within species.118,120 The conservation of 
SAA through evolution is demonstrated with equine SAA which has a high homology with SAA 
from dog (80.6%), mink (77.5%), human (76.9%) and duck (71.9%).121 This homology of SAA 
proteins and genes within eutherian mammals122 includes also other vertebrates like 
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marsupials123 and fish,124 as well as invertebrates as the echinoderm Holothuria glaberrina (Sea 
Cucumber); suggesting that SAA has survived for more than 500 million years.125 The SAA 
complementary deoxyribonucleic acid (cDNA) in the horse is 480 nucleotides in length encoding 
an SAA precursor protein of 128 amino acids.121 To yield a mature SAA protein of 110 residues, 
post-transcriptional cleavage of the precursor protein occurs after glycine at position 18.121 
Extra-hepatic synthesis of SAA has been reported in various species such as rabbits, 
minks, mice,126 bovine,107 horses127 and humans.126,128 Different SAA isoforms have been 
documented for these species. Isoforms SAA1 and SAA2 are synthetized by the liver, while 
SAA3 is mainly expressed at extrahepatic sites.117 The ‘acute-phase’ SAA includes the isoforms 
SAA1 and SAA2, which majorly circulates bound to HDL3 and a smaller quantity circulates free 
during inflammation.129 Expression of SAA3 (a pseudogene in humans)130 has been 
demonstrated in adipose tissue131 and in the mammary gland of cattle,132 as well as the isoform 
SAA3 has been quantified in colostrum from bovine, equine and ovine132 as well as in bovine 
milk during mastitis.133 In horses, SAA3 has been demonstrated in peritoneal fluid,134 
colostrum132 and synovial fluid.127 Also, SAA3 messenger ribonucleic acid (mRNA) expression 
has been demonstrated on equine endometrium during uterine Escherichia coli infection.135  
A ‘constitutive’ SAA is a fourth isoform (SAA4) found on several tissues within the 
body, is minimally induced during inflammation and has been found bound to HDL in healthy 
individuals.107,117 In healthy horses, moderate (>1% of the hepatic expression) SAA4 mRNA 
expression was found in the mammary gland, lung, synovial membrane, pancreas, thymus, 
thyroid and uterus.107 Low expression (<1% of the hepatic expression) was also documented on 
adipose tissue, adrenal gland, aorta, brain, colon, jejunum, stomach, heart, kidney lymph nodes, 
ovary, testis, prostate, skeletal muscle, cardiac muscle, skin and spleen.107 Constitutive SAA 
(SAA4) has only a degree of 50% of similarity in the amino acid sequence with the acute-phase 
SAA (SAA1 and SAA2) suggesting that constitutive SAA may represent a separate protein 
family having different functions.117 The differences in amino acid sequences of SAA proteins 
within different tissues have led to suggest that each SAA protein may adapt to a particular 
function in each particular tissue.128 
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2.4.2 Transport through the bloodstream and metabolism of serum amyloid A 
 
Serum amyloid A is an apolipoprotein that circulates in plasma in its majority bound to 
HDL3.105,106 In individuals with normal levels of SAA, about 0.1% of the total HDL3 is bound to 
SAA.106 Just after SAA is synthesized, it is primarily incorporated into HDL3 (occupying about 
1% of the total HDL3 protein in serum during inflammation), and a minority can be associated 
with other lipoproteins containing apoN-100, low-density lipoprotein (LDL) and very low-
density lipoprotein (VLDL). During inflammation, SAA increases to high concentrations in 
serum and becomes the major apolipoprotein bound to HDL3, but some SAA also remains 
unbound in serum.136 During an APR, the concentration of free SAA (not bound to HDL3) 
increases in serum and can form aggregates.137 It has been suggested that the free form of SAA is 
the form that binds to a variety of receptors, which will be described in the following sections.137 
Serum amyloid A is degraded in the liver110 after a short plasma half-life. This has been 
estimated to be from 75 to 80 minutes in mice, with a 95% clearance from plasma 6 h after the 
synthesis has stopped.111 The exact half-life of SAA in horses is unknown but its plasma levels 
increase 3 to 6 h after an inflammatory stimulus, peaking on day 3 and returning to baseline 
levels by day 4,119,138 demonstrating that equine SAA may have a similar short half-life as the 
one described in mice.40  
 
2.5 Serum amyloid A biological functions 
  
 Most of the research on the biological functions of SAA originates from the human 
literature. The reported functions of SAA in mammals are varied and poorly understood.107 In 
addition, many pitfalls have been identified in these studies.139 Serum amyloid A may have 
different functions and could serve as a first defense mechanism against inflammatory stimuli.117 
It can bind to several cell surface receptors and activate the target cells, but no SAA-specific 
receptor has been identified.139 It has been suggested that SAA may be important to modulate 
several immune-inflammatory reactions that include inhibition of the activation of 
polymorphonuclear leukocytes,140 induction of cyclooxygenase metabolites in mononuclear 
leukocytes,141 and induction of mononuclear and polymorphonuclear leukocyte phagocytosis and 
chemotaxis.142,143 Protective functions of SAA have also been documented. Serum amyloid 3 can 
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induce intestinal mucin production in human intestines causing a reduction in the adherence of 
enteropathogenic Escherichia coli to the HT29 human intestinal cells.144 Also, SAA3 has 
cytokine-like properties being chemotactic to various cell types and binding to the surface of 
Gram-negative bacteria.145 Furthermore, SAA from porcine milk have shown to have LPS-
binding capacity.146 It has also been reported that SAA has several functions associated with the 
maintenance of normal functions through its effects on lipid transportation,128 and collagenase 
synthesis.147 The specific known biological functions of SAA will be discussed in the following 
sub-sections. 
 
2.5.1 Regulatory mechanisms of serum amyloid A 
 
Interleukin 1β is a key cytokine during inflammation and two separate signals are 
necessary to induce its secretion.148 The first signal is necessary to induce the synthesis of pro-
IL-1β and the second signal induces the formation of an intracellular protein platform called the 
inflammasome. The inflammasomes mediate the conversion of pro-IL-1β into its biologically 
active form.148,149 This conversion is mediated by activation of caspase-1 protease.148,149 Serum 
amyloid A induces the release of mature IL-1β by stimulating the two necessary signals in 
neutrophils,150 mast cells,151 macrophages152 and dendritic cells.153 The regulation of SAA over 
production of mature IL-1β has been shown to be predominantly by activation of the 
inflammasome NLRP3.152 
 
2.5.2 Serum amyloid A role in immunity 
 
 Serum amyloid A is a mediator of the innate immune system and also regulates the 
adaptive immune response.32,142 Its specific functions depend on the type of target cell and the 
local concentration of SAA.32,142 In humans, neutrophils are induced to produce TNFα, IL-1β, 
and IL-8 by SAA;150 while mast cells are induced to produce TNFα and IL-1β.151 SAA-induced 
mononuclear cells express several pro-inflammatory cytokines (TNFα, IL-1β, IL-6, and IL-8) as 
well as the growth-promoting granulocyte-macrophage colony-stimulating factor (GM-CSF).154 
Serum amyloid A also serves as a chemo-attractant for polymorphonuclear leukocytes and 
monocytes,142 and induces directional migration of human mast cells.155 
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 Serum amyloid A is a powerful pro-inflammatory mediator as it can bind and activate 
several structurally diverse receptors as well as induce activation of several signaling 
pathways.156,157 The activation of Toll-like receptor 4 (TLR4) by SAA increases the production 
of nitric oxide by macrophages.158 By activation of formyl peptide receptor-like 1 (FPRL1) in 
neutrophils, SAA induces release of FPRL1-dependent calcium, IL-8 and TNFα.159 In 
monocytes, the activation of the same receptor by SAA induces secretion of both anti- and pro-
inflammatory cytokines (IL-10 and TNFα, respectively).160 By FPRL1, SAA also induces 
phagocyte migration to the injured tissue.161 
 
2.5.3 Anti-inflammatory properties of serum amyloid A 
 
 The known anti-inflammatory properties of SAA are promoting the release of interleukin 
10 (IL-10)154 and inhibiting the oxidative burst in neutrophils.140  Serum amyloid A has also an 
effect on the proliferation of regulatory T cells.162 This effect has been suggested to be indirect 
by inducing a microenvironment that supports proliferation of regulatory T cells.162 
 
2.6 Serum amyloid A as a marker of systemic inflammation in horses 
 
Serum amyloid A is a good marker of systemic inflammation. It has very low basal 
values that can increase up to 1000 times during an APR.119 Its serum levels are not affected by 
sex (except for a moderate increase after parturition), and mild changes have been reported 
between different age groups.119 Concentrations of SAA can rise to different ranges depending 
on the amount of tissue damage. These concentrations decrease quickly after resolution of the 
tissue damage because of the SAA’s short half-life.40,119 In humans, its concentration in serum 
rises to higher levels in response to bacterial stimulus than to viral infection or non-infectious 
inflammation.141  
The basal values of SAA in serum of healthy horses are <30 mg/L,119,163-165 with certain 
variability observed depending on the assay used.40 In horses with experimentally-induced 
systemic inflammation (by intramuscular administration of turpentine oil) SAA concentrations 
rose within 6 h and reached their serum peak concentration 2 days later with a 20-fold increase 
from pre-treatment values.119  
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 A recent study evaluated the clinical application of the assessment of SAA in a 
specialized equine practice.166 A total of 212 horses were included and classified as clinically 
normal or clinically abnormal. The clinically abnormal horses had a variety of infectious or 
inflammatory conditions and all of them had significantly higher concentration of SAA in serum 
compared to the clinically normal horses. The authors of the study concluded that the assessment 
of SAA concentrations in clinically abnormal horses might be of value for monitoring disease 
and as a prognostic indicator.166  
Serum amyloid A, fibrinogen, haptoglobin and alpha1-acid-glycoprotein were recently 
detected in high concentrations in saliva of horses with systemic inflammation, suggesting that 
measurement of these APPs in saliva might be useful in monitoring disease.167 In another study 
on mares on late pregnancy where placentitis was induced; SAA and haptoglobin concentration 
in serum increased rapidly and remained increased until abortion occurred. This finding 
suggested that these APPs might be useful in monitoring placentitis.168 Moreover, SAA and 
surfactant protein D were increased in experimental bacterial pneumonia in horses, implying 
they might be useful in monitoring the clinical progression of this disease.169  
In a report on horses with colic, the quantification of SAA systemic concentrations 
helped in identifying horses with colic attributed to disease that have inflammation as a primary 
component of pathogenesis, as enteritis, colitis, peritonitis, or abdominal abscesses.170 
Furthermore, SAA were significantly increased in peritoneal fluid and serum from horses with 
colic. In the latter study, there was a strong correlation between paired serum and peritoneal fluid 
SAA concentrations.134 The authors concluded that SAA in peritoneal fluid and serum are 
potential valuable diagnostic markers for inflammatory abdominal conditions.134  
Contrary to these results, the use of SAA in serum from foals with Rhodococcus equi 
pneumonia was not reliable as an ancillary diagnostic tool or as a screening test for early 
detection of disease during the first month post-partum.171 Similarly, SAA was found to remain 
low during experimental infection of horses with Strongylus vulgaris larvae.172  
 
2.7 Serum amyloid A in synovial fluid 
 
 The role of serum amyloid A in synovial fluid is still not well understood.173 Serum 
amyloid A is known to be involved in several pro-inflammatory reactions that may lead to 
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destruction of the tissues within the joint.173,174 These are mainly induction of chemokines, 
attraction of leukocytes, angiogenesis, and induction of MMPs synthesis.173,174 Furthermore, 
SAA is involved in cholesterol metabolism in inflamed tissues and therefore, in the local release 
of pro-inflammatory molecules.139 
 
2.7.1 The role of serum amyloid A in rheumatoid arthritis 
 
Serum amyloid A has been detected in the synovial membrane from rheumatoid patients 
as well as in their synoviocytes.175 The presence of SAA in human synovial fluid has an 
important role in the pathogenesis of inflammatory arthritis (rheumatoid arthritis, psoriatic 
arthritis, sarcoid arthritis, and undifferentiated arthritis) by inducing the production of MMPs, 
which are associated with cartilage degeneration.174,176,177 It induces the synthesis of IL-6,178 IL-
23 p19 and p40179 in synovial fibroblasts from patients with rheumatoid arthritis. The Th17 type 
of immune response is important during rheumatoid arthritis and SAA increases expression of 
IL-1β by the inflammasome NLRP3,179 which promotes the development of Th17 response.153 
Also, in synovial fibroblasts, SAA induces IL-6 and IL-8 expression by activation of the receptor 
for the advanced glycation end products (RAGE) and acting as a pro-inflammatory cytokine.180 
 
2.7.2 The role of serum amyloid A in osteoarthritis 
   
 Osteoarthritis is considered a progressive degenerative disease with constant cartilage 
breakdown, osteophyte formation and subchondral bone thickening.181 Recently, SAA functions 
during both inflammation and metabolic pathways have been investigated.182 Serum amyloid A 
was detected in sections from osteoarthritic cartilage174 as well as its concentrations were 
increased in plasma from osteoarthritic patients.183 Also, SAA in synovial fluid and plasma 
increases with radiographic progression of osteoarthritis in human patients.183,184 The level of 
SAA in plasma was higher than in synovial fluid in a range of 3 to 44 fold indicating a passive 
diffusion of SAA from circulating fluid to the synovial fluid and not the opposite.183  
The induction of cytokines (IL-6 and IL-8) and MMPs (MMP-1, MMP-3 and MMP-13) 
by SAA has been described during osteoarthritis183 similar to what has been described during 
rheumatoid arthritis.173 The induction of different inflammatory mediators by SAA supports an 
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important role of SAA in the pathophysiological process of osteoarthritis in humans.183 Although 
only slight increases in serum and synovial fluid SAA concentrations have been reported in 
humans with osteoarthritis185,186 it has been suggested that SAA could be an earlier marker of 
joint damage than radiographic imaging as well as a prognostic and disease activity 
indicator.187,188 In horses, only one study has reported SAA during osteoarthritis as well as 
osteochondrosis189 indicating low or undetectable concentrations in serum and synovial fluid. 
Interestingly, in the latter study more synovial fluid samples from osteoarthritic joints had SAA 
concentrations above the detection limit of the assay than serum samples, which may reflect 
local synthesis of SAA in absence of a systemic response.189  
Contrary to the known anti-inflammatory effects of glucocorticoids, these medications 
can induce SAA secretion (a pro-inflammatory mediator) in osteoarthritic joints.183 This effect of 
glucocorticoids is not yet well understood.183 
 
2.7.3 Serum amyloid A in synovial fluid from horses 
 
Three SAA isoforms have been recognized in the equine serum.127,129 Five isoforms were 
reported in synovial fluid in experimental arthritis induced by intra-articular injection of 
lipopolysaccharides (LPS).127 Three of these isoforms were also found in serum and the 
remaining two only in synovial fluid. These findings indicate that isoforms produced by the liver 
(SAA1 and SAA2) can access the synovial cavity and that synthesis of equine SAA also occurs 
intra-articularly (SAA3) similar to what has been demonstrated in articular chondrocytes and 
synoviocytes in rabbits147 and humans.175,176,183 
Serum amyloid A concentration in synovial fluid in horses may serve as a good marker 
for septic synovitis as it has been detected in high concentrations in synovial fluid during septic 
arthritis and after experimentally induced synovitis by LPS (experimental model for septic 
arthritis/synovitis).127,189 In healthy equine joints, synovial concentrations of SAA are frequently 
undetectable and have been reported from <0.2 to 0.7 mg/L.94,127 Twenty four hours to 48 h after 
experimental intra-articular injection of LPS127, SAA concentrations in synovial fluid were 
increased to 100 to 1500 mg/L (>100-fold increase). A systemic response also occurred and was 
characterized by increased concentrations of SAA in serum. The magnitude of the systemic and 
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articular responses was dependent on the intra-articular LPS dose. These values decreased 
promptly to undetectable values when clinical improvement was noticed.  
In a study that investigated the concentrations of SAA in serum and synovial fluid from 
healthy horses and horses with joint diseases, SAA in synovial fluid was found to be increased to 
high concentrations (>100-fold increase) during septic arthritis compared to concentrations in 
healthy joints.189 In this study, ten healthy joints (controls) had low to undetectable systemic and 
synovial concentrations of SAA; meanwhile four horses with confirmed septic arthritis had 
moderate to high systemic and synovial SAA concentrations. Also in the same study, two other 
horses with penetrating wounds had low initial SAA concentrations in synovial fluid, which 
decreased with joint lavage and anti-inflammatory drugs as well as antimicrobial treatment. The 
time from injury to sampling in these two latter horses is not reported and this could have 
influenced the reported low values of SAA, as concentrations of SAA are known to increase at 4 
to 8 h in synovial fluid.127 In this same study,189 3 horses with septic arthritis had undetectable to 
very low concentrations of SAA in synovial fluid. In two of these 3 horses, synovial fluid 
samples were only taken after treatment for synovial sepsis was completed (nucleated cell counts 
were already normal in these two horses when sampling). The third horse received intra-articular 
corticosteroids 12 days before sampling, which according to the author of the report might have 
influenced the SAA response. Due to the heterogeneity of the clinical cases reported on the latter 
study, results are difficult to interpret and a study evaluating synovial SAA concentrations in a 
large number of confirmed clinical cases of septic arthritis is needed. A promising recent study 
evaluated the use of SAA concentrations in synovial fluid to differentiate between non-septic 
arthritis and septic arthritis using a new semi-quantitative colorimetric SAA test (snap test) 
compared to a quantitative ELISA.190 The new test had a good specificity (93.3%) and sensitivity 
(84.6%) showing increased values of synovial SAA in 13 septic synovial samples and low values 
in 15 non-septic synovial samples.190 Unfortunately the latter report is currently accessible only 
as a proceeding abstract and no further details are available. 
When the effect of repeated arthrocentesis and repeated intra-articular administration of 
amikacin on synovial and systemic SAA concentrations were evaluated in healthy equine joints, 
systemic and synovial concentrations of SAA remained at baseline values.189 In another study, 
SAA in synovial fluid was used to evaluate the effect of morphine in horses with experimentally 
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induced synovitis by intra-articular LPS.191 The concentrations of SAA reduced significantly 
after intra-articular administration of morphine, compared to control joints.191 
  
2.8 Methods for determination of equine serum amyloid A concentration 
 
Different methods have been used for measurement of SAA in equines. These methods 
include electroimmunoassay,192 single radial immunodiffusion,119 enzyme-linked immunosorbent 
assay (ELISA)193 and latex agglutination immunoturbidometric assay.163 A commercially 
available immunoturbidometric assay (LZ test SAA) that was first developed for the 
measurement of human SAA has been validated in horses.164 This method has an acceptable 
intra- and inter-assay variability (1.6% to 24.4% and 4.6% to 33.2%, respectively) with better 
precision at intermediate and high SAA concentrations compared to low SAA concentrations. 
The imprecision at low SAA concentrations does not influence the clinical interpretation of 
results, as horses develop high SAA concentrations (SAA increase from basal values of <30 
mg/L to 100 or >1000 mg/L) during the inflammatory response.163,164,192,194 The lower limit of 
quantification of the assay was 0.48 mg/L with a mean of 0.22 mg/L ± 0.086 when used in 
serum. A newer study performed an in-house validation of the immunoturbidometric assay in 
serum and synovial fluid obtaining an intra-assay variability in synovial fluid ranging from 1% to 
10% with a lower limit of quantification of 0.05 mg/L; while in serum the intra-assay variability 
ranged from 0.8% to 16% with a lower limit of quantification of 0.21 mg/L.94 This 
immunoturbidometric assay is automated and fast, and is being used in several diagnostic 
laboratories in Europe and North America for routine SAA measurements on horse serum and 
synovial fluid.40 It has also been successfully used on serum and synovial fluid in different 
studies.94,127,189,191  
A newer latex agglutination turbidometric immunoassay based on monoclonal anti-
human SAA antibodies has been validated for equine, feline and canine use.195 This test might be 
associated with a stronger long-term and inter-batch performance.195 A new semi-quantitative 
colorimetric SAA test (snap test) has recently been developed and used in synovial fluid from 
horses.190 This new test has shown good specificity (93.3%) and sensitivity (84.6%) to diagnose 
synovial sepsis in horses.190  
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All of the methods of quantification found in the literature and used in horses are based 
on human anti-SAA antibodies and to date no assay specific to equine SAA is available. A pilot 
study reported an attempt on purifying equine SAA to further develop a specific assay for use in 
equine.196 As explained earlier, SAA has a high homogeneity between species and therefore the 
use of human assays to quantify equine SAA is feasible. 
 
2.9 Other synovial fluid markers used in the diagnosis of septic arthritis 
 
 Lactate in normal synovial fluid is 2.02 ± 0.76 mmol/L (range 0.42 to 3.9 mmol/L) and 
increased to values greater than 4.9 mmol/L in 66% of equine tarsocrural joints after being 
inoculated with Staphylococcus aureus.26 In the latter study, the control joints were injected with 
saline and lactate remained less than 4.4 mmol/L.26 The pH in synovial fluid can decrease from 
its normal value of 7.3 ± 0.06 to values below 6.9 during infection and may be of help in 
diagnosing septic synovitis.26,197 Also serum and synovial fluid glucose difference (SSGD) has 
shown to be useful in diagnosing septic synovitis.26 The normal glucose content in synovial fluid 
is usually the same or marginally lower than that of serum (SSGD reference value of 0.85 ± 0.59 
mmol/L) and the SSGD has shown to increase to values greater than 2.2 mmol/L in 83% of 
synovial fluid samples from infected joints.26 Although all these parameters are easy and quick to 
measure, they are not uniformly reliable and therefore it has been suggested in the literature they 
should not be used as a primary diagnostic parameter.26,53 
 Nucleated cells are generally predominant during septic synovitis and are the main source 
of pro-MMP-9.21,198 This form of metalloproteinase (measured through gelatin zymography) is 
increased in synovial fluid from infected joints.21,198,199 In one study, septic synovial fluid had 
higher concentrations of proactive and active MMP-9 compared to non-septic arthritis.198 Also, 
the concentration of pro-MMP-9 was predictive of survival as well as the ratio of pro-MMP-9 to 
pro-MMP-2.21 Unfortunately these assays are not ease to run and therefore are not widely 
available to be used in regular practice.21 
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2.10 Conclusions 
 
 The success in treating septic arthritis varies between studies but all of them agree on the 
importance of appropriate diagnosis, monitoring and treatment. Several diagnostic and 
prognostic factors have been discussed and all of them should be considered with caution and in 
parallel with a thorough clinical examination of each clinical case. Treatment for septic synovitis 
can be aggressive and it can have a large effect on the unspecific synovial markers of 
inflammation that are traditionally used for diagnosis and monitoring of this condition. As 
previously mentioned, arthroscopic and through-and-through joint lavages can produce an 
increase in the synovial concentrations of inflammatory markers to values associated with sepsis. 
Therefore, the common synovial inflammatory markers should not be used alone and new and 
more specific markers of synovial infection are needed to diagnose and to monitor sepsis.  
The clinical use of serum amyloid A, an acute phase protein very sensitive to 
inflammation, has recently been investigated in equine medicine. The functions of serum 
amyloid A are not totally understood and a variety of these were presented within this literature 
review. The majority of the research found in the literature is based on humans and the number 
of studies in horses is still low. Elucidation of the functions of SAA within the synovial cavity 
during sepsis could bring a higher understanding of the pathologic processes involved during 
infection and possibly, ways to reduce the detrimental effects of septic synovitis. Meanwhile, 
SAA can increase to high concentrations during septic synovitis in horses and not during other 
low-inflammatory diseases as reviewed previously; it is not affected by repeated arthrocentesis 
or repeated intra-articular administration of amikacin. These procedures are commonly 
performed to diagnose and treat septic synovitis. Further validation of SAA is still needed; and 
the effect of other common procedures, performed as treatment for septic synovitis, on the 
concentrations of SAA should be investigated and is the main stem of this thesis. These 
procedures include two important means of performing lavage of a synovial structure and are 
arthroscopic lavage and repeated through-and-through joint lavage. Assessing the effect of these 
invasive procedures in SAA concentrations in synovial fluid will help in the validation of 
synovial SAA as a marker of synovial sepsis, as well as in the understanding of its unknown 
functions in the joint during pathologic processes.  
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CHAPTER 3: EFFECT OF ARTHROSCOPIC LAVAGE ON SYNOVIAL FLUID 
CONCENTRATIONS OF SERUM AMYLOID A, TOTAL PROTEIN AND NUCLEATED 
CELL COUNT IN HEALTHY HORSES. 
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3.1 Abstract 
 
Objective: To evaluate the effect of arthroscopic lavage on systemic serum amyloid A (SAA) 
and SAA, total protein, nucleated cell count and percentage of neutrophils in synovial fluid in 
healthy horses. 
 
Study Design: Prospective, two-period, cross-over study. 
 
Animals: Six healthy horses. 
 
Methods: Middle carpal joints were randomly assigned to one of the following treatments 1) 
arthrocentesis (controls) or 2) arthroscopic lavage with 30-day washout period between 
treatments. Synovial fluid and blood samples were collected at 0, 24, 48, 72, 96 and 120 h. 
Measurements included systemic and synovial fluid SAA, as well as total protein, nucleated cell 
count and percentages of neutrophils in synovial fluid. Data was analyzed by median quantile 
regression and Wilcoxon signed-rank test and significance level set at p<0.05. 
 
Results: Systemic and synovial fluid SAA did not increase from baseline (except systemic SAA 
at 24 h for both treatments) and were not significantly different between treatments. Total protein 
values were significantly increased after arthroscopic lavage (except at 96 h) but not in controls 
at all-time points. With both treatments, nucleated cell counts significantly increased from 
baseline values at all-time points. Percentages of neutrophils were significantly increased after 
arthroscopic lavage at all-time points whilst only at 24 h in controls. 
 
Conclusions: Total protein, nucleated cell count and percentage of neutrophils values in 
synovial fluid were significantly increased after arthroscopic lavage, however synovial fluid 
SAA was not affected by this procedure. Further research is warranted to validate synovial fluid 
SAA as a monitoring tool during treatment of septic arthritis. 
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3.2 Introduction 
 
Commonly used synovial fluid parameters for diagnosing and monitoring sepsis in a 
synovial structure are total protein, nucleated cell count and percentage of neutrophils. The 
reference values for normal synovial fluid have been documented as a total protein of <25 g/L, 
nucleated cell count <1 x 109 cells/L and neutrophils being less than 10% of the nucleated 
cells.54,55 Sepsis has typically been considered when synovial fluid yields a total protein higher 
than 40 g/L, a nucleated cell count above 30 x 109 cells/L and neutrophils comprising greater 
than 80% of the nucleated cells.53,54 However, some authors have suggested synovial sepsis with 
values of nucleated cell counts ≥ 5 x 109 cells/L.4,8,11,19 Cytological examination and culture of 
synovial fluid can also aid in the diagnosis of synovial sepsis although bacteria are not always 
evident on cytology or isolated from cultures.11,24 The most prominent cells identified on 
cytological examination during sepsis are neutrophils, yet degenerative changes are often not 
present.11,24,53  
These synovial fluid parameters can be largely affected by the common procedures 
performed to treat septic arthritis. A study performed in healthy joints found total protein in 
synovial fluid to be mildly increased 8 and 14 days post-arthroscopic lavage to values of 27.6 ± 
6.5 g/L and 23.1 ± 4.9 g/L, respectively.79 Additionally, in a recent study performed in healthy 
joints, total protein peaked at 24 h and nucleated cell count reached values higher than 20 x 109 
cells/L at 12 h after arthroscopic lavage with Lactated Ringer’s Solution (LRS).78 Furthermore, 
repeated arthrocentesis and repeated intra-articular administration of amikacin every 48 h caused 
an increase of total protein and nucleated cell count to values in the range of septic arthritis.94 
Currently, these are the only diagnostic methods available to the majority of equine practitioners. 
This indicates the need for a new marker that is not affected by the high volume lavage used as 
part of the treatment for septic arthritis. Subsequently, this marker could accurately diagnose and 
monitor the response to treatment and establish if further treatments are required. 
Serum amyloid A (SAA) is an acute-phase protein that has been investigated as a marker 
for septic arthritis.189 Although it is primarily synthetized by the liver, it can also be synthesized 
by other tissues like synoviocytes, in the presence of infection.127 A reference range for systemic 
SAA concentrations (0.5-20 mg/L) has been reported in healthy horses and those values can have 
a 100 to 1000-fold increase in response to infectious or inflammatory conditions.119,163,194 
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Furthermore, systemic SAA concentrations significantly increased in 11 horses that underwent 
arthroscopic removal of a unilateral osteochondritic lesion of the distal intermediate ridge of the 
tibia with concentrations that peaked at 48 to 72 h and returned to pre-operative values 5 days 
after surgery.200 The effect of general anesthesia alone on systemic SAA was evaluated in one 
small study (including only 2 horses) resulting in no effect on systemic SAA.192 
Concentrations of SAA in synovial fluid in healthy horses are frequently undetectable 
and have been reported from <0.2 to 0.7 mg/L.94,189 In clinical cases of septic arthritis189 and 24 
to 48 h after experimental intra-articular injection of LPS127, synovial fluid SAA concentrations 
were increased to 100 to 1500 mg/L. These values decreased promptly to undetectable values 
when clinical improvement was noticed. Moreover, synovial fluid SAA concentrations were not 
affected by either repeated arthrocentesis or repeated intra-articular administration of amikacin.94 
This suggests that synovial fluid SAA responds in different magnitude to inflammation than to 
sepsis, whereas the commonly used synovial fluid parameters total protein, nucleated cell count 
and percentage of neutrophils may respond identically to non-septic and septic inflammation. 
However, to the authors’ knowledge the effect of arthroscopic lavage on synovial fluid SAA 
concentrations in horses has not been evaluated. If synovial fluid SAA is not influenced by the 
high volume lavage performed during arthroscopy, this will suggest it may have a clinical value 
to be used for monitoring and evaluating sepsis in a joint previously treated by arthroscopic 
lavage. 
The objective of this study was to evaluate the effect of arthroscopic lavage on systemic 
and synovial fluid SAA concentrations, as well as the effects on total protein, nucleated cell 
count and percentage of neutrophils in synovial fluid in healthy horses. It was hypothesized that 
synovial fluid SAA concentrations would not significantly increase from baseline values 
following arthroscopic lavage, whereas total protein, nucleated cell count and percentage of 
neutrophils in synovial fluid would increase. 
 
3.3 Materials and Methods 
 
A randomized prospective, two-period, cross-over trial was performed in 6 American 
Quarter Horses (3 mares and 3 geldings) with a mean age ± SD of 7 ± 4 years (range 3 to 14 
years) and mean ± SD body weight of 488 ± 29 kg (range 460 to 535 kg). Prior to enrollment, 
	   35	  
horses were considered healthy and free of musculoskeletal pathology based on thorough 
physical examination, lameness examination, and complete blood work (complete blood count, 
biochemistry profile, and measurement of systemic SAA). Physical and lameness examinations 
were performed blindly by one investigator (JLB) on each horse every 24 h during the study and 
24 h after collection of the last sample. Physical examination entailed: mentation, heart rate, 
respiratory rate, rectal temperature, mucous membrane color, capillary refill time, and abdominal 
and thoracic auscultation. Lameness examination was performed at the walk and trot on a 
straight line on hard surface, before and after flexion of the carpi.  
 
3.3.1 Procedures 
 
For this study, each horse underwent 2 study trials under general anesthesia (control and 
arthroscopic lavage). Horses and limbs were randomized with a commercial statistics software 
program (Stata Corp, College Station, TX) to each treatment at the beginning of the study. A 30-
day washout period was allowed between treatments; thereafter the contralateral limb received 
the opposite treatment. 
Horses that received arthroscopic lavage were premedicated with xylazine hydrochloride 
(1mg/kg intravenously IV), induced with ketamine (2 mg/kg IV) mixed with propofol (0.4 mg/kg 
IV) and maintained with isoflurane. Horses were positioned in dorsal recumbency and the 
assigned carpus was clipped, aseptically prepared and draped in a routine fashion for 
arthroscopic surgery. A 3 mL synovial fluid sample of the middle carpal joint was collected prior 
to arthroscopy using a 22-gauge needle placed into the dorsomedial synovial pouch of the middle 
carpal joint with the carpus flexed at approximately 70-degrees and labelled as “Time 0”. A 10-
mm skin incision was made to create a lateral arthroscopic portal halfway between the extensor 
carpi radialis tendon and the common digital extensor tendon and midway between the third and 
intermediate carpal bones with the joint flexed at approximately 70-degrees. A second 10-mm 
skin incision was then made medial to the extensor carpi radialis tendon and midway between 
the radial and third carpal bones. The middle carpal joint was then distended with 10 mL of 
sterile saline using the needle that had been previously inserted to collect the synovial sample. 
The joint capsule was incised through the lateral skin incision and a 300 - 4.0 mm arthroscope 
(Richard Wolf GmbH, Knittlingen, Germany) was inserted into the joint as routinely performed 
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in clinical cases.201 Arthroscopic examination of the middle carpal joint was first performed 
using a fluid irrigation pump (Endomat® SCB n. Hamou®, Karl Storz GmbH & Co. KG, 
Tuttlingen, Germany). A fluid pump setting of maximal pressure of 100 mmHg and a fluid rate 
of 300 mL/min were used for initial articular examination. When observed during arthroscopic 
examination, abnormalities in cartilage, synovial membrane or ligaments were documented and 
graded.202 A medial portal was made through the dorsomedial skin incision in similar manner to 
the lateral portal and a 4.5 mm egress cannula (Karl Storz GmbH & Co. KG, Tuttlingen, 
Germany) was placed and used as an egress portal. The egress cannula was directed as far as 
possible from the arthroscope and in a different direction to prevent a direct outflow. Copious 
lavage of the middle carpal joint was performed with a fluid pump setting of 100 mmHg and a 
fluid rate of 600 mL/min using 10 L of LRS. Skin incisions were closed using 2-0 monofilament 
polybutester using a cruciate suture pattern. A light sterile bandage consisting of a non-adherent 
pad, kling gauze and adhesive bandage was then placed to cover the incisions. A blood sample (4 
mL) was collected directly from the jugular vein during surgery (time 0 h) by an assistant. 
Anesthesia and surgery times were recorded. Anesthesia time was defined as the time from 
delivery of induction drugs to the moment of extubation. Surgical time was defined as the time 
from creation of the first incision to closure of arthroscopic portals. Horses recovered unassisted 
in a padded recovery stall. Skin sutures were removed two weeks after arthroscopy. 
Control horses were placed under general anesthesia with the same anesthestic protocol 
and the assigned carpus was clipped and aseptically prepared in a similar fashion. Arthrocentesis 
of the middle carpal joint was performed to collect 3 mL of synovial fluid as previously 
described and labelled as “time 0 h”. A blood sample (4 mL) was collected directly from the 
jugular vein at the same time. Anesthesia time was recorded and horses were kept under general 
anesthesia for 90 minutes as an estimated time required to perform arthroscopic lavage in clinical 
cases. A light sterile bandage was applied on the treated joint in the same manner as on the limbs 
that received arthroscopic lavage and horses recovered as described previously. 
 
3.3.2 Postoperative sampling and monitoring 
 
Physical and lameness examinations were performed blindly in both groups and as 
previously described at 24, 48, 72, 96 and 120 h after general anesthesia. After each examination 
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horses were sedated with detomidine (0.005 to 0.006 mg/kg IV), bandages were removed and 
synovial fluid samples (3 mL) were collected from the middle carpal joint by one of the 
investigators (AST). Sterile technique was used to place a 22-gauge needle into the dorsolateral 
synovial pouch of the assigned middle carpal joint. The number of needle replacements required 
to obtain a synovial fluid sample was recorded each time. The same investigator who performed 
the arthrocenteses (not blinded to treatment distribution) documented subjectively heat, pain and 
joint effusion as mild, moderate or severe. A blood sample was collected from the jugular vein at 
the same time points as arthrocenteses.  
 
3.3.3 Sample analysis 
 
Synovial fluid samples were assessed macroscopically by one of the investigators (JLB) 
who was blinded to treatment distribution. Blood contamination was subjectively classified on a 
scale from 0 to 4 as follows: 0) clear with no signs of blood contamination, 1) one drop of blood 
or hemorrhagic color at needle-end of syringe, 2) mildly hemorrhagic, slightly uniform red color, 
3) moderately hemorrhagic, uniform red color but still translucent and 4) severely hemorrhagic, 
uniformly red not translucent. Total protein in synovial fluid was measured immediately after 
collection directly from the syringe using a standard refractometer (Reichert GmbH, Seefeld, 
Germany). Samples were then transferred into two EDTA tubes (1.5 mL each).  
A single board certified clinical pathologist (HJB) who was blinded to treatments, 
examined one aliquot of the synovial fluid sample.  Subjective assessment of color, clarity and 
presence or absence of solid material was performed. A direct smear was made before the sample 
was treated with hyaluronidase (hyaluronidase from bovine testes; type VIII lyophilized powder 
300- 1000 U/mg; SIGMA®, St. Louis, MO). Nucleated cell counts were obtained using an 
automated hematology analyzer (Abbott Laboratories, IL) and a cytocentrifuge preparation 
(Shandon Southern Instruments Inc., PA) was prepared for each sample.  All slides were stained 
using a Romanowsky stain (Fisher Scientific Company L.L.C., Middletown, VA). Cytology 
slides were subjectively assessed for cellular preservation, degree of hemodilution and presence 
of etiologic agents. A 100 cell differential count was performed on each sample using the 
cytocentrifuge preparation. 
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The other aliquot of synovial fluid and the blood samples were centrifuged at 2100 g for 
15 minutes (Beckman Coulter Inc., Germany). Synovial fluid supernatant and serum were stored 
at -80 °C for further SAA quantification. Quantification of systemic and synovial fluid SAA was 
performed using a human SAA turbidometric immunoassay (Eiken Chemical Co., Tokyo, Japan) 
previously validated for use in equine164 and used on previous studies on equine synovial 
fluid.94,127,189 Previous to quantification of SAA by an automated chemistry analyser (F. 
Hoffmann-La Roche Ltd, Basel, Switzerland), 10 uL of hyaluronidase (SIGMA®; 500 U/mL, 
prod. No. H4272, lot SLBB1402V) were added to 490 uL of synovial fluid to reduce synovial 
fluid viscosity. 
 
3.3.4 Statistical analysis 
 
All data was analyzed with a commercial statistics software program (Stata 12, 
StataCorp, College Station, TX, USA). Descriptive statistics (means, standard deviations, 
medians, percentiles, stem and leaf plots, quantile plots and histograms) were used to summarize 
the distribution and central tendency of the independent and dependent variables. Normality of 
data was assessed using the Shapiro-Wilk test and variables with p<0.05 were interpreted as not 
normally distributed. As many of the outcomes measured were not normally distributed, non-
parametric statistics were used for evaluation. The outcomes compared included total protein, 
nucleated cell count, percentage of neutrophils, systemic SAA and synovial fluid SAA 
concentrations. Values of SAA that were below the lower limit of quantification of the assay 
were interpreted as “0” (zero) for statistical analysis. Quantile regression was used to model the 
median value of each of the outcomes in separate models with treatment, time and an interaction 
term (treatment x time). The treatment medians were separated by time using the Wilcoxon 
signed-rank test. Significance level was set at p<0.05. 
 
3.4 Results 
 
All horses remained healthy and sound throughout the entire study. The mean ± SD 
anesthesia time for horses undergoing arthroscopic lavage was 72.6 ± 17.2 minutes and for 
controls was 85.3 ± 7.84 minutes. Mean ± SD surgical time to infuse 10 L of LRS was 24 ± 2.1 
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minutes. Mild synovial fluid effusion of the middle carpal joint was noticed after arthroscopic 
lavage. The effusion was not associated with heat or pain on palpation and resolved within 5 
days without further treatment. One carpus developed mild effusion of the extensor carpi radialis 
tendon sheath after arthroscopic lavage with no associated pain, heat or lameness. This resolved 
itself within 4 days without medical treatment. In all carpi explored by arthroscopy, no 
abnormalities were noticed in cartilage, synovial membrane or ligaments except for one.  This 
latter carpus had grade 2 cartilage lesions extending down to <50% of cartilage depth202 with 
change in color and ‘wear lines’ in the cartilage surface, increased synovial villi density and 
thickening. No osteochondral fragments, fractures or ligaments abnormalities were observed. 
Both carpi in this horse had values considered normal on all measured synovial fluid markers at 
the beginning of the study. 
Synovial fluid samples from control carpi were clear with no evidence of contamination 
from peripheral blood at all sampling times except from two horses. One of these had blood 
contamination at only one sampling time (72h; score 2). The second horse had blood 
contamination at various sampling times graded as score 1 at 0, 72 and 96 h and score 3 at 24 
and 48 h. Twenty-four hours after arthroscopic lavage, all synovial fluid samples were scored as 
4 and were turbid and very viscous, improving progressively to score 3 at 96 h. By the end of the 
study (120 h), all samples from the arthroscopic lavage treated carpi improved to score 2 and 
were amber in color, slightly cloudy and slightly viscous except for samples from one carpus 
which remained severely hemorrhagic during all sampling times (score 4). The former was the 
only carpus from the arthroscopic lavage treatment in which needle replacement was performed 
(at 3 sampling times). Only one horse in the control group had the needle replaced and at one 
sampling time point. 
 
3.4.1 Protein concentrations in synovial fluid 
 
Figure 1 summarizes synovial fluid total protein values. Baseline values were not 
significantly different between treatments. Overall total protein median of arthroscopic lavage 
treatment was significantly higher than controls’ median (p=0.01). 
Total protein values after arthroscopic lavage (all time points except baseline) ranged 
from 20.0 to 61.0 g/L with a median of 34.5 g/L. Total protein values significantly increased 
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(p<0.05) 24 h after the procedure and remained increased (p<0.05) until the end of the study 
(except at 96 h). In the control carpi, after the first arthrocentesis, total protein values (overall of 
all times except baseline) ranged from 10.0 to 42.0 g/L with a median of 28.0 g/L and did not 
significantly increase compared to baseline values. When median values at each sampling time 
were compared between treatments, total protein value was significantly higher after 
arthroscopic lavage than in controls only at 24 h (p<0.05). 
 
3.4.2 Nucleated cell count in synovial fluid 
 
Figure 2 summarizes synovial fluid nucleated cell count values. Baseline values were not 
significantly different between treatments. Overall, nucleated cell count medians were not 
significantly different between groups.  
Nucleated cell count values ranged from 0.4 to 23.3 x 109 cells/L with a median of 1.5 x 
109 cells/L after arthroscopic lavage (overall of all times except baseline) and from 0.2 to 7.1 x 
109 cells/L with a median of 1.1 x 109 cells/L after the first arthrocentesis (overall of all times 
except baseline). In both groups, nucleated cell count significantly increased at all time points 
when compared to baseline values (p<0.05). After arthroscopic lavage the nucleated cell count 
was significantly higher than controls only at 24 h (p<0.05). 
 
3.4.3 Percentage of neutrophils in synovial fluid 
 
Figure 3 summarizes the percentage of neutrophils obtained. Baseline values were 
significantly different between treatments (p=0.03). There was no significant difference between 
treatments when comparing their overall percentage of neutrophils medians. 
Percentage of neutrophils values after arthroscopic lavage (overall of all times except 
baseline) ranged from 4% to 88% with a median of 49.5% and significantly increased 24 h after 
arthroscopic lavage (p<0.05). Values remained significantly increased after arthroscopic lavage 
until the end of the study compared to baseline values. In the control carpi, percentages of 
neutrophils ranged from 3% to 76% with a median of 39.5% (overall of all times except 
baseline) and were only significantly increased from baseline values at 24 h (p<0.05). When 
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median values at each sampling time (excluding baseline values) were compared between 
treatments, there was no significant difference between groups. 
 
3.4.4 Serum amyloid A in synovial fluid 
 
Figure 4 summarizes synovial fluid SAA values. Baseline values were not significantly 
different between treatments. There was no significant difference between treatments when 
comparing their overall synovial fluid SAA medians. 
Synovial fluid SAA (overall of all times except baseline) ranged from less than the lower 
limit of quantification (LOQ) of the assay (0.2 mg/L)94,164 to 1.3 mg/L with a median of <LOQ 
after arthroscopic lavage and from <LOQ to 4 mg/L with a median of <LOQ after the first 
arthrocentesis. Two control horses had values higher than values seen in normal horses in 
previous studies94,189 at 48 h (1.3 mg/L and 4 mg/L), as well as one horse 24 h after arthroscopic 
lavage (1.3 mg/L). The values obtained on these 3 horses are represented as outliers in Figure 4. 
In both groups, synovial fluid SAA did not significantly increase from baseline values. There 
was no significant difference when values of synovial fluid SAA at each sampling time were 
compared between treatments. 
 
3.4.5 Systemic serum amyloid A 
 
Figure 5 summarizes systemic SAA values. Baseline values were not significantly 
different between treatments. There was no significant difference between groups when 
comparing their overall systemic SAA medians. 
Systemic SAA values (overall of all times except baseline) ranged from <LOQ to 92.7 
mg/L with a median of 0.4 mg/L after arthroscopic lavage and from <LOQ to 243.7 mg/L with a 
median of 0.3 mg/L after the first arthrocentesis. Two control horses had a maximal increase of 
systemic SAA (130.8 mg/L and 243.7 mg/L) at 48 h. One treated horse had a maximal increase 
of systemic SAA 24 h after arthroscopic lavage (92.7 mg/L). These 3 horses were the same 
horses reported to have a mild increase on synovial fluid SAA and their SAA values are 
represented as outliers in Figure 5. Systemic SAA values in both groups significantly increased 
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compared to baseline values only at 24 h (p<0.05). There was no significant difference when 
values at each sampling time were compared between treatments. 
 
3.5 Discussion 
 
Arthroscopic lavage with copious fluids is an important aspect in the treatment of septic 
arthritis.4 In our study synovial fluid SAA was not affected by this procedure while total protein, 
nucleated cell count and percentage of neutrophils values were all increased when compared to 
baseline values. These findings, supported by the fact that synovial fluid SAA increases to high 
concentration during septic arthritis189, suggest that synovial fluid SAA may be valuable for 
monitoring the response of septic joints treated by arthroscopic lavage. Further studies assessing 
synovial fluid SAA as a monitoring tool during treatment of septic arthritis are needed and 
should include sequential measurements of synovial fluid SAA in clinical cases.  
Carpi that received arthroscopic lavage had a significant increase in total protein, 
nucleated cell counts and percentages of neutrophils in synovial fluid. Most total protein values 
at 24 h were within the reported range for septic arthritis (≥40 g/L).54,55 In addition, significant 
increase in the values of nucleated cell counts up to 23.3 x 109 cells/L were observed at 24 h after 
arthroscopic lavage which can be considered consistent with sepsis. Furthermore, median values 
of percentages of neutrophils were significantly increased after arthroscopic lavage and some 
values were within the reported range for septic arthritis (≥80%).4,8 Values of a similar 
magnitude were obtained in a recent study in healthy tarsocrural joints after being distended, 
followed with lavage with LRS for 30 minutes.78 An earlier experimental study reported 
significant changes in synovial fluid markers in normal joints at days 8, 14, 21 and 28 after 
arthroscopic lavage and after arthroscopic partial synovectomy.79 Direct comparison with their 
results cannot be made as in the previous study, samples were taken 8 days post-operatively and 
the immediate inflammatory response after arthroscopy was missed. Nevertheless, clinicians 
should be aware that the commonly used synovial fluid markers to evaluate sepsis are 
nonspecific as they can significantly increase after arthroscopic lavage in a manner similar to 
synovial sepsis. Therefore, their use to monitor the progression of sepsis postoperatively can be 
challenging. 
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The effect of repeated arthrocentesis on synovial fluid markers has been evaluated in 
previous studies with similar results.94,203 In our study, values of total protein, nucleated cell 
counts and percentages of neutrophils in control carpi remained below the values considered for 
septic arthritis except for one total protein value obtained at 96 h (42 g/L). This higher value 
could be due to an individual response to repeated arthrocentesis. Although our results are 
similar to a recent study where arthrocentesis was performed every 48 h94, total protein in two 
control carpi in our study were higher than the published normal value (<25 g/L)54,55 at 0 h. 
These two total protein values and the difference found between groups in the percentage of 
neutrophils at the beginning of the study could be an effect of blood contamination when 
sampling or a sub-clinical synovitis that was not detected during our physical and lameness 
examination at the beginning of the study. Our values for total protein, nucleated cell counts and 
percentages of neutrophils in control carpi are very similar to those of a previous report in tendon 
sheaths after more frequent synovial centesis with one single injection of LRS.203 However, 
another study reported a significant increase in total protein after repeated arthrocentesis with 
intra-articular injection of saline solution instilled at each arthrocentesis.189 These differences in 
total protein values between studies may be associated with different study designs. 
During arthroscopic lavage of clinical cases of septic arthritis, two or more egress portals 
may be used in an attempt to achieve thorough removal of fibrin or pannus, especially if present 
in the palmar synovial pouches.41 One single egress portal was used in this study and precautions 
were taken to avoid direct flow between the inflow and outflow of the lavage solution by placing 
the arthroscope (ingress) far from the egress cannula and directing both in different directions 
within the joint. The authors believe this was sufficient to create a thorough lavage of the joint as 
these were all healthy joints and no pannus or fibrin was present during the lavage.  
One carpus developed distension of the extensor carpi radialis tendon sheath possibly by 
inadvertent penetration of the sheath during creation of the portals. The change in synovial fluid 
markers found in this carpus is similar to the rest of carpi that received arthroscopic lavage and 
therefore the distension encountered in the tendon sheath had no effect on our results.  
One carpus had signs of cartilage degeneration observed during arthroscopic 
examination. The contralateral carpus acted as a control and the synovial fluid markers behaved 
similar to the other carpi that served as controls. The authors believe that the significant changes 
in the synovial markers in this specific carpus after arthroscopic lavage can be accounted to the 
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procedure and not to the pathological cartilage degeneration itself.  Interestingly, neither 
systemic nor synovial fluid SAA in either carpus were elevated. This correlates with a previous 
report of SAA levels in horses with osteoarthritis and osteochondrosis.189 
Systemic SAA significantly increased at 24 h in both groups. A moderate increase in 3 
horses after general anesthesia (2 controls and 1 after arthroscopic lavage) to values up to 243.7 
mg/L, could be responsible for this statistical significance. The cause for this increase is 
unknown. It is suspected it could be associated to sub-clinical conditions aggravated by 
anesthesia, procedures related to anesthesia (catheter placement, intubation, prolonged 
recumbency) or to anesthesia itself which can cause a mild transient respiratory inflammatory 
response.204 Previous research has shown significant increase of systemic SAA values after 
elective arthroscopic removal of an osteochondritic lesion.200 However, 2 of the 3 horses that had 
increased systemic SAA values in our study were controls and consequently only arthrocentesis 
was performed under general anesthesia. This disagrees with a previous small study performed 
on 2 horses where general anesthesia alone had no effect on systemic SAA.192 The present study 
was not designed to evaluate the effect of anesthesia alone on systemic SAA; therefore further 
studies on the effect of anesthesia on systemic SAA are warranted. 
Portal creation and capillary lesions of the highly vascularized synovial membrane during 
arthroscopic lavage could be responsible for the synovial samples graded as score 4 encountered 
24 h after arthroscopic lavage. The presence of blood in the joint itself can be partially 
responsible for the increase in synovial fluid markers and can also cause further inflammation 
increasing total protein and neutrophil concentrations.205 In our study, all synovial fluid samples 
from the arthroscopic lavage treated carpi were scored as 4 (according to our blood 
contamination scoring) at 24 h after arthroscopic lavage. The samples improved progressively to 
a score 3 by 96 h and by the end of the study almost all samples improved to a score 2. This 
finding is supported by a recent study in which samples were found to be red 12 h after 
arthroscopic lavage with LRS and remained red until the end of the study (48 h).78 Furthermore, 
in another study, samples collected at 8, 14, 21 and 28 days after arthroscopic lavage were found 
to be slightly hemorrhagic even at 28 days.79  
The effect of blood contamination on synovial fluid SAA concentration cannot be 
evaluated in this study as all horses had low concentrations of systemic SAA. The 3 horses 
reported in this study that had a moderate increase in their systemic SAA after general anesthesia 
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showed a mild (not statistically significant) increase in synovial fluid SAA to values higher than 
values seen in normal horses in previous studies.94,189 Serum amyloid A isoforms from serum 
were detected in synovial fluid in a previous study.127 Therefore, the authors suspect the increase 
in synovial fluid SAA found in these 3 horses could derive from systemic SAA infiltration into 
the joint by either direct blood contamination or by capillary diffusion. However, the effect of 
contamination of synovial fluid with systemic SAA is still unclear and further studies should be 
performed to evaluate its effect on synovial fluid SAA quantification. Meanwhile, caution should 
be taken when interpreting synovial fluid SAA values from horses with systemic inflammation 
(e.g. foals with septicemia).  
Arthroscopic lavage altered the common synovial fluid markers and in some cases these 
markers reached the cut-off value for sepsis. These synovial fluid markers seem to respond in the 
same manner to non-septic and septic inflammation, which could complicate evaluation of a joint 
for sepsis while treatment is installed. Synovial fluid SAA was not affected in either treatment 
groups in this study and is known to increase 100 to 1000-fold from its normal concentrations 
during sepsis.189 Therefore, SAA may serve as a more accurate marker for monitoring sepsis than 
total protein, nucleated cell count and percentage of neutrophils when measured in synovial fluid 
from horses that have undergone arthroscopic lavage. Further research in clinical cases is still 
needed before recommending synovial fluid SAA as a monitoring tool during treatment for 
septic arthritis. Furthermore, caution should be taken when interpreting synovial fluid SAA from 
horses with systemic inflammation until further research is available. Additional evaluation of 
synovial SAA as a marker of sepsis in clinical cases after arthrocentesis and arthroscopic lavage 
is warranted. 
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Figure 1. Box plot of median (circles) total protein concentrations (g/L) in synovial fluid from 
control middle carpal joints (dotted line; blue) and middle carpal joints after arthroscopic lavage 
(solid line; red) in healthy horses. Bottom and top of box corresponds to 25th and 75th percentiles, 
respectively. Whiskers correspond to maximum and minimum values. n Outliers. XSignificant 
difference (p<0.05) from baseline. +Significant difference (p<0.05) between treatments. 
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Figure 2. Box plot of median (circles) nucleated cell counts (x109 cell/L) in synovial fluid from 
control middle carpal joints (dotted line; blue) and middle carpal joints after arthroscopic lavage 
(solid line; red) in healthy horses. Bottom and top of box corresponds to 25th and 75th percentiles, 
respectively. Whiskers correspond to maximum and minimum values. n Outliers. XSignificant 
difference (p<0.05) from baseline. +Significant difference (p<0.05) between treatments. 
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Figure 3. Box plot of median (circles) percentage of neutrophils (%) in synovial fluid from 
control middle carpal joints (dotted line; blue) and middle carpal joints after arthroscopic lavage 
(solid line; red) in healthy horses. Bottom and top of box corresponds to 25th and 75th percentiles, 
respectively. Whiskers correspond to maximum and minimum values. n Outliers. XSignificant 
difference (p<0.05) from baseline. +Significant difference (p<0.05) between treatments. 
 
 
	   49	  
 
 
Figure 4. Box plot of median (circles) SAA concentrations (mg/L) in synovial fluid from control 
middle carpal joints (dotted line; blue) and middle carpal joints after arthroscopic lavage (solid 
line; red) in healthy horses. Bottom and top of box corresponds to 25th and 75th percentiles, 
respectively. Whiskers correspond to maximum and minimum values. n Outliers. XSignificant 
difference (p<0.05) from baseline. +Significant difference (p<0.05) between treatments. 
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Figure 5. Box plot of median (circles) systemic SAA concentrations (mg/L) from control middle 
carpal joints (dotted line; blue) and middle carpal joints after arthroscopic lavage (solid line; red) 
in healthy horses. Bottom and top of box corresponds to 25th and 75th percentiles, respectively. 
Whiskers correspond to maximum and minimum values. n Outliers. XSignificant difference 
(p<0.05) from baseline. +Significant difference (p<0.05) between treatments.
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4.1 Abstract 
 
The objective of this study was to evaluate the effect of through-and-through joint lavage 
on systemic and synovial SAA; as well as total protein, nucleated cell count and percentage of 
neutrophils in synovial fluid of 6 healthy horses. A prospective experimental study was 
performed where one tarsocrural joint of each horse was randomly assigned to receive repeated 
through-and-through joint lavage at 0, 48 and 96 h. Synovial fluid and blood samples were 
collected at 0 (baseline), 24, 48, 72, 96 and 120 h. Systemic and synovial SAA, total protein, 
nucleated cell count and percentage of neutrophils were measured and compared to baseline. 
Data was analyzed using quantile regression and significance level set at p<0.05. Concentrations 
of systemic and synovial SAA were not increased from baseline. Total protein and nucleated cell 
counts were significantly increased from baseline (except for nucleated cell count at 96 h); and 
percentage of neutrophils values were not significantly increased. Repeated through-and-through 
joint lavage did not affect synovial SAA concentrations in horses, however synovial total protein 
and nucleated cell counts values increased. Some of the total protein and nucleated cell counts 
values observed in this study were within the range reported for septic arthritis 24 h after joint 
lavage. Synovial SAA may be a valuable marker to be used when evaluating the clinical 
progression of septic joints after through-and-through joint lavage. Clinical studies evaluating 
synovial fluid SAA concentrations while treating synovial sepsis with through-and-through joint 
lavage are warranted. 
 
4.2 Introduction 
 
Septic arthritis is a severe arthropathy with survival rates ranging from 62% in foals to 
85% in adult horses11 and only 48.3% to 65.8%206,207 of the horses that survive will regain 
athletic function. Treatment can be performed in various modalities including arthroscopic 
lavage19 and through-and-through joint lavage of the affected synovial structure.57 These 
procedures are usually combined with administration of antimicrobials by intra-articular 
injections or by intravenous regional limb perfusion.87 The preferred procedure to lavage an 
infected joint is by arthroscopy.19 However, in many occasions because of economical 
constraints or anesthetic risk, septic joints are successfully treated by repeated through-and-
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through joint lavage.57 Because of the limited debridement and the lower volume of lavage fluids 
that through-and-through joint lavage allows in comparison with arthroscopy; through-and-
through joint lavage is usually repeated to increase the likelihood of clinical success.57 
Bacteria are not always evident on cytology or isolated from cultures11 and therefore 
diagnosis of synovial sepsis is usually relied upon total protein, nucleated cell count and 
percentage of neutrophils in synovial fluid. Reference values in normal synovial fluid have been 
established as total protein of <25 g/L, nucleated cell count <1 x 109 cells/L and neutrophils 
being less than 10% of the total nucleated cells.54 Sepsis has typically been considered with total 
protein higher than 40 g/L, nucleated cell count above 30 x 109 cells/L and neutrophils 
comprising greater than 80% of the total nucleated cells.54 However, other authors have 
suggested synovial sepsis with values of nucleated cell count ≥5 x 109 cells/L.11,19  
Practitioners usually rely on sequential cytological examination of synovial fluid samples 
as a guideline for therapy adjustments and prognosis.12,57 Unfortunately, repeated intra-articular 
administration of antimicrobials,94 repeated arthrocentesis,203 arthroscopic lavage208 and a single 
through-and-through joint lavage80,82,83 can result in similar cytological changes as those 
associated with septic arthritis. Therefore, common synovial fluid parameters are not reliable 
especially after the joint has been treated.  
Serum amyloid A in synovial fluid increases from undetectable or very low 
concentrations in healthy joints (<0.2 to 0.7 mg/L),94,189 to high concentrations during synovial 
sepsis (100-1500 mg/L).189 Its concentrations are not affected by repeated arthrocenteses,94,189 
intra-articular administration of amikacin94 or arthroscopic lavage.208 A single through-and-
through joint lavage has been reported to affect the common inflammatory markers.80,82,83 
However, the effect of repeated through-and-through joint lavage on these markers and on 
synovial SAA concentration has not been investigated. 
The objective of this study was to evaluate the effect of repeated through-and-through 
joint lavage on systemic and synovial SAA concentrations; as well as total protein concentration, 
nucleated cell count and percentage of neutrophils in synovial fluid from healthy equine 
tarsocrural joints. We hypothesized that synovial SAA will not change from baseline values after 
repeated through-and-through joint lavage while the other synovial parameters will increase 
significantly. 
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4.3 Material and Methods 
 
Six healthy adult American Quarter Horses (7 ± 3.5 years; 525 ± 64 kg b.w.t.) were used 
for this prospective experimental study. The University Animal Care and Use Committee 
approved all experimental procedures. Horses were considered healthy and free of 
musculoskeletal pathology on the basis of results of a thorough physical examination, lameness 
examination, complete blood work (CBC and biochemistry profile including measurement of 
systemic blood SAA) and radiographic assessment of the tarsi (4 standard views). 
A tarsocrural joint in each horse was randomly assigned by a commercial statistics 
software program (Stata Corp.) to receive repeated through-and-through joint lavage at times 0, 
48 and 96 h. Samples of synovial fluid were taken immediately before performing the joint 
lavage and at times 24, 72 and 120 h. Synovial fluid parameters measured at all time points 
included: total protein, nucleated cell count, percentage of neutrophils and synovial SAA. A 
blood sample was collected in a serum tube by jugular venipuncture at all time points before 
arthrocenteses was performed. Serum and synovial fluid samples taken at 0 h were used as 
baseline values and served as controls for further statistical analysis. Physical and lameness 
examinations were performed every 24 h on all horses until the last sampling (120 h) and 7 days 
after the third lavage. 
Horses were restrained in stocks and sedated with detomidine hydrochloride (0.02 mg/kg 
IV) and butorphanol tartrate (0.03 mg/kg IV). The assigned tarsus was clipped and aseptically 
prepared. Prior to joint lavage, 3 mL of synovial fluid was collected from the dorsomedial pouch 
of the tarsocrural joint using a 22G, 3.8 cm long needle.209 The sample was then separated in two 
aliquots (1.5 mL each) and placed into two EDTA tubes. The number of attempts to obtain a 
synovial fluid sample (needle replacements) was recorded, as well as any complication found 
while lavage was performed. 
Through-and-through lavage of the tarsocrural joint was performed after synovial 
collection using a 14G, 3.8 cm long needle, inserted perpendicular to the skin into the 
dorsomedial pouch, medial to the saphenous vein and approximately 2.5 cm distal to the level of 
the palpable medial malleolus.209 A second 14G, 3.8 cm long needle was then inserted 
perpendicular to the skin into the dorsolateral pouch of the tarsocrural joint lateral to the extensor 
tendons just below the palpable lateral malleolus of the tibia. Sterile pump tubing was attached to 
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the needle inserted in the dorsomedial joint pouch and 3 L of LRS were infused using a 
peristaltic fluid pump (Spencer Varistaltic Dispenser and Pump, Manostat) at a flow setting of 
150 mL/min. After lavage was performed, excess fluid was evacuated from the joint before 
retrieving the needles. Light bandages consisting of sterile non-adherent pad (Medline Industries 
Inc.), kling gauze (Covidien) and adhesive bandage (BSN Medical) were applied.  
 
4.3.1 Sample Analysis 
 
A single clinical pathologist, who was blinded to times of collection and study protocol, 
examined one aliquot of the synovial fluid sample.  Subjective assessment of color, clarity and 
presence or absence of solid material was performed. Samples were subjectively graded for 
blood contamination in a blinded fashion according to a scale from 0 to 4 as follows: 0) clear 
with no signs of blood contamination, 1) slightly uniform hemorrhagic color, 2) mildly 
hemorrhagic, mild uniform red color, 3) moderately hemorrhagic, uniform red color but still 
translucent or 4) severely hemorrhagic, uniformly red and not translucent. Total protein was 
determined through refractometry (Reichert GmbH). A direct smear was made before the sample 
was treated with 0.1 mg of hyaluronidase (hyaluronidase from bovine testes; type VIII 
lyophilized powder 300 to 1000 U/mg; SIGMA). Nucleated cell count was obtained using an 
automated hematology analyzer (Abbott Laboratories). A cytocentrifuge preparation (Shandon 
Southern Instruments Inc.) was prepared and stained using a Romanowsky stain (Fisher 
Scientific Company L.L.C.). Cytological examination was subjectively assessed for cellular 
preservation and presence of etiologic agents. A 100 cell differential count was performed on 
each sample using the cytocentrifuge preparation.  
The second aliquot of synovial fluid and blood samples were centrifuged at 2100 g for 15 
minutes (Beckman Coulter Inc.). Synovial fluid supernatant and serum were stored at -80 0C. 
When collection of all samples was finalized, synovial fluid and serum samples were thawed at 
room temperature. Ten µL of hyaluronidase (SIGMA; 500 U/mL) were added to 490 µL of 
synovial fluid to reduce its viscosity. Quantification of systemic and synovial SAA was 
performed on an automated chemistry analyzer (F. Hoffmann-La Roche Ltd) using a human 
SAA turbidometric immunoassay (Eiken Chemical Co.) previously validated for equine use.164 
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4.3.2 Statistical Analysis 
 
All data was analyzed with a commercial statistics software program (Stata 12IC, Stata 
Corp.). Descriptive statistics were used to summarize the distribution and central tendency of the 
independent and dependent variables. Many of the measured outcomes were not normally 
distributed and non-parametric statistics were used for evaluation.  Quantile regression was used 
to compare the baseline median value of each of the outcomes at each sampling time point in 
separate models. The outcomes included total protein, nucleated cell count, percentage of 
neutrophils, systemic SAA and synovial SAA concentrations. The degree of blood contamination 
and needle replacements were individually tested as potential confounding variables for all 
outcomes in the quantile regression models. The overall significance of each confounding 
variable in the models was tested with an F-test. Significance level was set at p<0.05. 
 
4.4 Results 
 
All horses remained healthy and did not show lameness throughout the study. Joint 
lavage was performed successfully in all horses with minor complications. These included 
movement of the horse during the procedure, which resulted in flexion of the limb and short 
interruption of the egress flow. The mean ± SD time to infuse 3 L of LRS was 23 ± 3 minutes. 
Mild effusion of the treated tarsocrural joint was noticed after the first lavage in all horses and 
resolved within seven days after performing the last joint lavage. The effusion was not associated 
with heat or pain on palpation.  
When obtaining synovial fluid samples, needle replacement with a new 22G needle 
occurred in 9 out of 36 samples because of movement of the horse when sampling or insufficient 
synovial fluid quantity collected. When needle replacement was evaluated as a confounding 
variable it was found to have no influence on the outcomes. Baseline samples were subjectively 
scored according to the amount of blood contamination as grade 4 in two samples, grade 2 in one 
sample, grade 1 in one sample and grade 0 in two samples. In the rest of the sampling times (not 
including baseline), blood contamination was subjectively graded 4 in seven samples, 3 in eleven 
samples, 2 in eleven samples, and 0 in one sample. Blood contamination score was found to be a 
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confounding variable only to percentage of neutrophils (r2 = 0.44, P<0.001) and a higher blood 
contamination score indicated a higher neutrophil count.   
Total protein baseline values ranged from 10.0 to 25.0 g/L with a median of 12.5 g/L. 
Once repeated joint lavage was initiated, total protein values ranged from 15 to 60 g/L with a 
median of 26.0 g/L throughout the study. Concentrations of total protein peaked at 24 h after the 
first lavage and remained significantly increased compared to baseline at all time points (Figure 
6). 
Nucleated cell counts followed a similar pattern to the one reported for total protein. 
Baseline values ranged from 0.1 to 0.5 x 109 cells/L with a median of 0.3 x 109 cells/L. During 
the rest of the study, nucleated cell count values ranged from 1.6 to 38.4 x 109 cells/L with a 
median of 4.7 x 109 cells/L. Values of nucleated cell count peaked at 24 h and were significantly 
higher than baseline values at all time points, except at 96 h (p=0.138) (Figure 7). 
Baseline values for percentage of neutrophils ranged from 1 to 64% (median 23%). 
Throughout the study, values ranged from 21 to 78% with a median of 56%. There was no 
significant difference when compared baseline values (p>0.05) to the rest of the sampling times 
(Figure 8). 
Serum amyloid A concentrations in synovial fluid were below the reported lower limit of 
quantification of the assay (LOQ; 0.2 mg/L)94,164 at baseline; and remained <LOQ during the rest 
of the study (Figure 9). Systemic SAA baseline concentrations ranged from <LOQ to 0.6 mg/L 
with a median concentration of <LOQ. Throughout the study, systemic SAA values were ≤ LOQ 
with a median of <LOQ (Figure 10). Due to a small number of samples with values above the 
LOQ, SAA results could not be compared statistically.  
 
4.5 Discussion 
 
The results of this study showed that systemic and synovial concentrations of SAA were 
not altered by repeated through-and-through joint lavage, whereas total protein concentration and 
nucleated cell count values were altered. Additionally, increased concentrations of SAA in 
synovial fluid have been described during septic arthritis.189,190 Therefore, synovial SAA 
concentrations may be worthy of measuring to monitor treatment effect of repeated through-and-
through joint lavage in horses with septic arthritis.  
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To the authors’ knowledge this is the first report that has evaluated the effect of repeated 
through-and-through joint lavage on synovial inflammatory markers and direct comparison with 
other studies is not possible. However, reports after a single through-and-through joint lavage 
have shown a significant increase in total protein and nucleated cell count values in synovial 
fluid (≤ 53 g/L and ≤ 38 x 109 cells/L, respectively).51,82,83 In these studies, these inflammatory 
markers reached values that have been associated with synovial sepsis 24 h after the procedure, 
similar to the results found in our study. 
Previous studies have reported percentages of neutrophils values to be significantly 
increased 24 h after a single through-and-through joint lavage to values higher than the reference 
value for septic arthritis.80,82,83 We hypothesized that percentage of neutrophils will be 
significantly different from baseline values and the results of our study fail to prove this part of 
our hypothesis. However, the high variability of values obtained at the beginning of our study, 
possibly due to sample contamination with blood as shown by our statistical analysis, could be 
responsible for this observation.  
The majority of our samples had evidence of blood contamination after the first lavage 
and occurred throughout the rest of the study. This alteration in the color of synovial fluid after a 
single through-and-through joint lavage has been reported in other studies,80,82,83 supporting our 
results. 
In a previous clinical report, an average of three through-and-through joint lavage 
procedures were needed to resolve sepsis57 and our study was design to simulate this clinical 
scenario. Although several practitioners prefer placing needles in the palmar/plantar aspect of the 
joint in selected cases, the placement of two needles and the use of three liters of LRS in our 
study was enough to produce a moderate inflammatory response characterized by increased 
synovial total protein concentration and nucleated cell count to values associated with sepsis 24 h 
after the lavage. The effect of using more liters of LRS is unknown and warrants further 
investigation. On the other hand, the authors believe that placing more needles would likely have 
not modified the clinical significance of our results. 
A second group of tarsocrural joints receiving only repeated arthrocentesis and serving as 
controls was not implemented and maybe considered a limitation of the study. Repeated 
arthrocentesis has been evaluated in other experimental studies resulting in no changes on 
systemic and synovial SAA.94,189,208 However, the common synovial markers were reported to be 
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constantly altered after repeated arthrocentesis in previous studies.94,189,203,208 Inclusion of a 
control group sustaining repeated arthrocentesis was therefore considered unnecessary. 
Few studies have focused on assessing and monitoring treatment for septic arthritis. 
Persistent synovial infection during treatment demonstrated by positive bacterial culture reduces 
overall prognosis2 and it has been suggested that elevated nucleated cell count (>1 x 109 cells/L) 
and percentage of neutrophils (>30%) at 4 to 6 days after initiating treatment inferred a poor 
prognosis for athletic function.12 Also a total protein concentration of 50 to 55 g/L obtained after 
arthroscopy was recently associated with reduce likelihood of survival to hospital discharge.19 
Similar changes in total protein, nucleated cell count and percentage of neutrophils have been 
reported in healthy joints after repeated intra-articular administration of amikacin,94 arthroscopic 
lavage;208 and in the present study, after repeated through-and-through joint lavage. Therefore, 
there is a need for a marker that could assess promptly failure of treatment. This will help 
clinicians on making accurate and early decisions to adjust therapy accordingly as well as 
obtaining a precise prognosis.  
Serum amyloid A concentrations in healthy joints have been reported to be below the 
LOQ94,189,208 similar to our results. During septic arthritis these concentrations regularly increase 
to high values and decrease when clinical improvement is noticed.189,190 In our study, and as 
hypothesized, we proved that through-and-through joint lavage has no effect in systemic and 
synovial SAA as all values were <LOQ. Further evaluation of SAA concentrations in synovial 
fluid as a marker to assess resolution of sepsis while treatment for septic arthritis is installed, is 
warranted.  
Based on the results of this study, we believe that SAA may be a valuable marker to be used 
for monitoring sepsis during aggressive treatment with repeated through-and-through joint 
lavage. Additional prospective experimental studies evaluating synovial SAA during treatment 
of clinical cases of septic arthritis are needed before recommending its use.  
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Figure 6. Box plot of median (circles) total protein concentrations (g/L) after repeated through-
and-through joint lavage in 6 healthy horses. Bottom and top of box corresponds to 25th and 75th 
percentiles, respectively. Whiskers correspond to maximum and minimum values. XSignificant 
difference (p<0.05) from baseline. 
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Figure 7. Box plot of median (circles) nucleated cell counts (x 109 cells/L) after repeated 
through-and-through joint lavage in 6 healthy horses. Bottom and top of box corresponds to 25th 
and 75th percentiles, respectively. Whiskers correspond to maximum and minimum values. 
XSignificant difference (p<0.05) from baseline. 
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Figure 8. Box plot of median (circles) neutrophils (%) after repeated through-and-through joint 
lavage in 6 healthy horses. Bottom and top of box corresponds to 25th and 75th percentiles, 
respectively. Whiskers correspond to maximum and minimum values. XSignificant difference 
(p<0.05) from baseline. 
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Figure 9. Box plot of median (circles) serum amyloid A concentrations (mg/L) in synovial fluid 
after repeated through-and-through joint lavage in 6 healthy horses. Bottom and top of box 
corresponds to 25th and 75th percentiles, respectively. Whiskers correspond to maximum and 
minimum values. XSignificant difference (p<0.05) from baseline. 
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Figure 10. Box plot of median (circles) systemic serum amyloid A concentrations (mg/L) after 
repeated through-and-through joint lavage in 6 healthy horses. Bottom and top of box 
corresponds to 25th and 75th percentiles, respectively. Whiskers correspond to maximum and 
minimum values. XSignificant difference (p<0.05) from baseline. 
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CHAPTER 5: GENERAL DISCUSSION 
 
The effects of arthroscopic lavage and repeated through-and-through joint lavage on 
systemic and synovial SAA concentration, total protein concentration, nucleated cell count and 
percentage of neutrophils were successfully evaluated and discussed through this thesis. 
Although these procedures affected the common synovial inflammatory markers, SAA 
concentrations were not altered. The concentrations of SAA detected in our studies were low. 
Most of systemic and synovial SAA concentrations were <LOQ of the assay and remained low 
throughout the studies. In previous research, SAA concentrations were below the LOQ in healthy 
joints and increased in 100 to 1000-fold in septic synovial fluid.189,190 Also, repeated 
arthrocentesis and repeated intra-articular injections of amikacin have been tested before, 
resulting in no increase on systemic or synovial SAA concentrations.94,189 The fact that SAA is 
not affected by treatment for septic arthritis, but is increased during infection, might be of 
advantage when using SAA as a marker for resolution of sepsis while treatment is applied. 
Clinical studies evaluating SAA concentrations in synovial fluid are still needed before final 
recommendation of its use is given. 
Arthroscopic lavage and repeated through-and-through joint lavage had a major effect on 
the common synovial inflammatory markers. In other reports, these markers were also affected 
by repeated arthrocentesis and repeated intra-articular administration of amikacin.94,189 
Therefore, their sole use to monitor treatment success or failure is not recommended. A recent 
retrospective report of horses treated for septic arthritis argues this idea by claiming that horses 
with normal synovial fluid analysis at 4 to 6 days post-lavage had a better prognosis than horses 
with altered synovial inflammatory markers, and that the effect of treatment procedures on the 
common synovial markers is unfounded.12 This thesis along with two previous reports in normal 
horses78,79 have shown that the synovial inflammatory markers changes persist at 5 days post-
lavage and even at 28 days after lavage. Further trials in horses with experimentally induced 
septic arthritis should be performed to evaluate the effect of treatment under these circumstances. 
After general anesthesia, SAA had a mild increase in synovial fluid and a moderate 
increase in its systemic concentrations on two control horses and in one horse that received 
arthroscopic lavage. As discussed in the thesis, the effect of anesthesia on SAA is still unknown 
and an increase in systemic concentrations of SAA may have a significant effect on synovial 
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SAA concentrations. This might be of concern when assessing synovial fluid SAA 
concentrations in horses that have an ongoing systemic disease. Special caution should be taken 
when evaluating joint sepsis on septic foals with increased values of SAA in blood. Further 
studies evaluating the effect of systemic inflammation on synovial concentrations of SAA need 
to be performed before recommending SAA as a specific marker for septic synovitis. 
Synovial SAA concentrations could serve a specific (and still unknown) function during 
septic synovitis. This is supported by an in-vitro study where SAA was found to bind to the outer 
membrane protein A of Gram-negative bacteria.145 Another study also showed that SAA had 
LPS-binding capacity.146 These reported biological properties of SAA and the fact that SAA is 
not affected by procedures that induce non-septic inflammation, suggests that SAA may have a 
specific role related to bacterial infection and elimination, which warrants further investigation. 
The lack of changes in the concentrations of SAA in synovial fluid after high volume 
lavage by the two exposed procedures might be due to absence of a systemic stimulus to induce 
hepatic and maybe local production of SAA. After reviewing the current literature, there is only 
one study that mentions local synthesis of SAA within the joint and without a systemic response. 
This was reported in horses with osteoarthritis on which more synovial fluid samples had SAA 
concentrations above the LOQ of the assay than serum samples.189 The values found above the 
LOQ were still low values of SAA. This suggests that although local synthesis of SAA within 
the joint is present, this may not represent a great quantity of the total SAA measured and that 
the majority of SAA in the joint might originate from hepatic synthesis. Further studies in this 
aspect are still needed. 
The two studies within this thesis show that SAA is not affected by arthroscopic lavage 
and repeated through-and-through joint lavage. The known increase in synovial SAA 
concentrations during septic synovitis and the lack of change in synovial SAA concentrations 
reported here; suggests that quantification of synovial SAA over the common synovial 
inflammatory markers when evaluating a synovial cavity for sepsis that has undergone these 
procedures, could help in the monitoring of treatment. Further studies quantifying SAA through 
treatment of naturally-occurring or experimentally-induced septic synovitis are warranted. 
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CHAPTER 6: CONCLUSIONS AND FUTURE STUDIES 
 
Based on the results of the presented studies we can conclude that: 
 
• Arthroscopic lavage of the middle carpal joint in healthy horses under general anesthesia: 
o Significantly increased total protein concentrations in synovial fluid with some values 
being within the reference values for synovial sepsis. 
o Significantly increased nucleated cell counts in synovial fluid to values higher than 
normal but below the reference range for septic synovitis. 
o Significantly increased the percentage of neutrophils in synovial fluid throughout the 
study period, with values consistent with septic synovitis at 24 h and 48 h. 
o Did not have an effect on SAA concentrations in synovial fluid. 
o Significantly increased SAA concentrations in blood at 24 h, likely as a result from 
anesthesia or procedures related to anesthesia. 
• Repeated through-and-through lavage of the tarsocrural joint in healthy horses under general 
anesthesia:  
o Significantly increased total protein concentrations in synovial fluid, with values 
above the reference range for septic synovitis at 24 h and 72 h. 
o Significantly increased nucleated cell counts in synovial fluid to values above the 
reference range for septic synovitis at 24 h. 
o Did not have an effect on percentages of neutrophils in synovial fluid. However, 
some percentages approximate the reference range for septic synovitis. 
o Did not have an effect on systemic and synovial fluid SAA concentrations. 
• Repeated arthrocentesis of the middle carpal joint in healthy horses:  
o Did not significantly affect total protein concentrations in synovial fluid. However, 
some values were above the reference values for septic synovitis at 96 h. 
o Significantly increased nucleated cell counts in synovial fluid. However, values were 
below the reference range for septic synovitis. 
o Significantly increased the percentage of neutrophils in synovial fluid only at 24 h 
after the first arthrocentesis. 
o Did not have an effect on systemic and synovial fluid SAA concentrations. 
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The limitations of the presented studies include: 
 
• The effects of lavage procedures in healthy joints. The effect of these procedures on the 
studied inflammatory markers during septic synovitis may vary and differ from our results. 
• In a clinical setting, the studied lavage procedures are commonly used in combination with 
administration of local and systemic antimicrobials as well as systemic anti-inflammatories. 
Therefore, the effect of these procedures combined might differ from the results exposed in 
this thesis.  
• The assay used for quantification of SAA on the presented studies behaved in a reliable 
manner and has been validated for use in equine serum. However, formal validation of the 
assay for its use in equine synovial fluid is needed before recommending its clinical use.  
 
Future studies considered necessary by the author of this thesis include: 
 
The current literature available suggests that synovial SAA increases during septic 
synovitis and through this thesis we have demonstrated that is not affected by the studied lavage 
procedures and therefore, SAA may serve as a good marker for diagnosis as well as monitoring 
treatment of septic synovitis. Although a recent study evaluating a semi-quantitative colorimetric 
SAA test has shown good specificity and sensitivity when differentiating between non-septic and 
septic arthritis, the authors of the study claim that more clinical cases are needed to validate their 
results.190 Therefore, new studies should focus on validation of SAA as a marker for septic 
arthritis during clinical or experimentally induced disease. These studies should include analysis 
of synovial fluid SAA during acute and sub-acute stages. Determination of positive and negative 
predictive values of serum and synovial fluid SAA concentrations are necessary before 
recommending SAA as a marker for septic synovitis. 
The current assays validated for equine use include a human turbidometric 
immunoassay164 and a human latex agglutination immunoassay.195 These two assays are 
validated for use in equine serum and the former has been widely used in studies on equine 
synovial fluid. However, a formal validation of the assay for use in synovial fluid should be 
performed to obtain intra- and inter-assay variability values. Development of an assay using 
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equine anti-SAA antibodies might bring advantages over human SAA assays and should be 
attempted.196 
The reported values of SAA in synovial fluid from healthy joints range from <0.2 to 0.7 
mg/L.94 Only one report had values of synovial SAA higher than 0.7 mg/L with values of ≤4 
mg/L found in healthy joints.191 New studies should focus on obtaining reference values of SAA 
in synovial fluid of healthy horses. These should also include evaluation of SAA as a marker of 
involvement of bone or tendon in the septic processes and if SAA could serve as a prognostic 
indicator for survival and return to athletic performance. 
Quantification of the different SAA isoforms remains a challenge. Isoforms have slight 
molecular differences that need to be described before assays can be developed. These 
differences might be very small and the assays will need to be highly specific to differentiate 
between them. The value of developing isoform-specific assays will be dependent on the 
increase of the different isoforms during pathologic processes. This increase may not be to 
concentrations high enough for the assay to detect them or be significant. Studies regarding SAA 
isoform-specific increases during pathologic processes could be advantageous in elucidating the 
varied functions of SAA and further direct therapy for specific processes. 
Future studies on SAA in blood and synovial fluid as well as in other bodily fluids or 
tissues are vast. Elucidation of the biological functions of SAA as well as the use of SAA as a 
marker during different diseases and their stages are needed and warrant several years of intense 
research. 
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CHAPTER 8: APPENDICES AND SUPPORTING DOCUMENTATION 
 
8.1 Data for Chapter 4 
 
Table A1. Raw data after arthroscopic lavage 
Horse	  
	  
Treatment	  
	  
Time	  
(h)	  
TP	  
(g/L)	  
NCC	  
(x109	  cells/L)	  
Neutrophils	  
(%)	  
Systemic	  
SAA	  
(mg/L)	  
Synovial	  
SAA	  
(mg/L)	  
H1	   Control	   0	   22	   0.1	   5	   0	   0	  
H2	   Control	   0	   19	   0.1	   1	   0	   0	  
H3	   Control	   0	   15	   0.2	   9	   0.4	   0.1	  
H4	   Control	   0	   15	   0.1	   31	   0.2	   0	  
H5	   Control	   0	   35	   0.1	   14	   2.1	   0	  
H6	   Control	   0	   30	   0.1	   17	   0.2	   0	  
H1	   Arthroscopy	   0	   20	   0.1	   1	   0.3	   0.2	  
H2	   Arthroscopy	  	   0	   23	   0.1	   1	   0.4	   0.6	  
H3	   Arthroscopy	   0	   9	   0.1	   1	   0.3	   0	  
H4	   Arthroscopy	   0	   24	   0.2	   2	   0	   0.1	  
H5	   Arthroscopy	   0	   30	   0.1	   13	   0.2	   0.2	  
H6	   Arthroscopy	   0	   20	   0.1	   3	   0.3	   0	  
H1	   Control	   24	   33	   1.8	   52	   0.9	   0	  
H2	   Control	   24	   22	   1.4	   47	   0.6	   0	  
H3	   Control	   24	   18	   0.8	   31	   83.6	   0.3	  
H4	   Control	   24	   30	   1.6	   61	   0.3	   0	  
H5	   Control	   24	   28	   1.4	   58	   201.3	   2.1	  
H6	   Control	   24	   28	   1.1	   76	   0.2	   0	  
H1	   Arthroscopy	   24	   45	   1.6	   68	   0.3	   0.2	  
H2	   Arthroscopy	  	   24	   42	   9.1	   51	   92.7	   1.3	  
H3	   Arthroscopy	   24	   47	   17.7	   65	   3.7	   0	  
H4	   Arthroscopy	   24	   55	   4.7	   88	   1.5	   0.4	  
H5	   Arthroscopy	   24	   33	   10.3	   84	   1.7	   0.1	  
H6	   Arthroscopy	   24	   61	   23.3	   67	   0.4	   0	  
H1	   Control	   48	   38	   1	   7	   0.4	   0	  
H2	   Control	   48	   25	   0.3	   35	   0.3	   0	  
H3	   Control	   48	   20	   1.4	   20	   130.8	   1.3	  
H4	   Control	   48	   30	   0.8	   23	   0	   0	  
H5	   Control	   48	   21	   7.1	   55	   243.7	   4	  
H6	   Control	   48	   31	   3.7	   46	   0	   0	  
H1	   Arthroscopy	   48	   35	   1.2	   48	   0.3	   0	  
H2	   Arthroscopy	  	   48	   32	   2.6	   33	   63.1	   0.4	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H3	   Arthroscopy	   48	   37	   5.6	   35	   1.4	   0	  
H4	   Arthroscopy	   48	   30	   5.3	   82	   0.4	   0	  
H5	   Arthroscopy	   48	   36	   1.3	   55	   0.9	   0	  
H6	   Arthroscopy	   48	   45	   6	   53	   0.2	   0	  
H1	   Control	   72	   32	   1.4	   52	   0.2	   0	  
H2	   Control	   72	   28	   0.2	   38	   0.4	   0	  
H3	   Control	   72	   10	   0.9	   15	   61.5	   0.8	  
H4	   Control	   72	   30	   0.8	   7	   0	   0	  
H5	   Control	   72	   20	   3.1	   54	   124.6	   1	  
H6	   Control	   72	   30	   1.6	   45	   0	   0	  
H1	   Arthroscopy	   72	   28	   1.9	   53	   0.6	   0.1	  
H2	   Arthroscopy	  	   72	   20	   1.3	   46	   13.3	   0.2	  
H3	   Arthroscopy	   72	   28	   2	   19	   0.7	   0	  
H4	   Arthroscopy	   72	   36	   1	   75	   0.2	   0	  
H5	   Arthroscopy	   72	   37	   1.1	   27	   0	   0	  
H6	   Arthroscopy	   72	   41	   1.8	   26	   0.4	   0	  
H1	   Control	   96	   42	   2.1	   51	   0.1	   0	  
H2	   Control	   96	   26	   0.4	   43	   0.6	   0.5	  
H3	   Control	   96	   14	   0.7	   15	   3.8	   0	  
H4	   Control	   96	   30	   1.6	   24	   0.2	   0.2	  
H5	   Control	   96	   16	   1.3	   47	   17.8	   0.3	  
H6	   Control	   96	   31	   2.8	   66	   0.1	   0	  
H1	   Arthroscopy	   96	   34	   0.9	   8	   0.1	   0.2	  
H2	   Arthroscopy	  	   96	   20	   0.6	   60	   1.2	   0	  
H3	   Arthroscopy	   96	   28	   1	   10	   0.4	   0	  
H4	   Arthroscopy	   96	   32	   1.9	   68	   0.5	   0.3	  
H5	   Arthroscopy	   96	   26	   1	   23	   0.3	   0	  
H6	   Arthroscopy	   96	   40	   0.9	   51	   0.2	   0	  
H1	   Control	   120	   38	   0.8	   14	   0	   0	  
H2	   Control	   120	   26	   0.7	   32	   0.2	   0.4	  
H3	   Control	   120	   22	   0.6	   5	   0.4	   0	  
H4	   Control	   120	   39	   1.2	   12	   0.1	   0	  
H5	   Control	   120	   10	   0.8	   3	   1.7	   0	  
H6	   Control	   120	   23	   0.8	   41	   0.3	   0	  
H1	   Arthroscopy	   120	   32	   0.4	   32	   0.2	   0.2	  
H2	   Arthroscopy	  	   120	   26	   0.4	   25	   0.4	   0	  
H3	   Arthroscopy	   120	   24	   0.5	   4	   0	   0	  
H4	   Arthroscopy	   120	   48	   1.4	   44	   0.4	   0.1	  
H5	   Arthroscopy	   120	   30	   0.7	   21	   0.7	   0	  
H6	   Arthroscopy	   120	   36	   1.8	   64	   1.1	   0.4	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Table A2. Summary statistics for controls: p25, p50 (median) and p75; by time. 
 
Controls	  
Time	  
(h)	  
TP	  
(g/L)	  
NCC	  
(x109	  cells/L)	  
Neutrophils	  
(%)	  
Systemic	  SAA	  
(mg/L)	  
Synovial	  SAA	  
(mg/L)	  
0	  
	  
15	   0.1	   5	   0	   0	  
20.5	   0.1	   11.5	   0.2	   0	  
30	   0.1	   17	   0.4	   0	  
24	  
	  
22	   1.1	   47	   0.3	   0	  
28	   1.4	   55	   0.75	   0	  
30	   1.6	   61	   83.6	   0.3	  
48	  
	  
21	   0.8	   20	   0	   0	  
27.5	   1.2	   29	   0.35	   0	  
31	   3.7	   46	   130.8	   1.3	  
72	  
	  
20	   0.8	   15	   0	   0	  
29	   1.15	   41.5	   0.3	   0	  
30	   1.6	   52	   61.5	   0.8	  
96	  
	  
16	   0.7	   24	   0.1	   0	  
28	   1.45	   45	   0.4	   0.1	  
31	   2.1	   51	   3.8	   0.3	  
120	  
	  
22	   0.7	   5	   0.1	   0	  
24.5	   0.8	   13	   0.25	   0	  
38	   0.8	   32	   0.4	   0	  
Total	  
	  
20	   0.5	   14	   0.1	   0	  
27	   0.85	   31.5	   0.3	   0	  
30.5	   1.5	   49	   1.9	   0.25	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Table A3. Summary statistics for arthroscopic lavage group: p25, p50 (median) and p75; 
by time. 
 
Arthroscopic	  lavage	  
Time	  
(h)	  
TP	  
(g/L)	  
NCC	  
(x109	  cells/L)	  
Neutrophils	  
(%)	  
Systemic	  SAA	  
(mg/L)	  
Synovial	  SAA	  
(mg/L)	  
0	  
	  
20	   0.1	   1	   0.2	   0	  
21.5	   0.1	   1.5	   0.3	   0.15	  
24	   0.1	   3	   0.3	   0.2	  
24	  
	  
42	   4.7	   65	   0.4	   0	  
46	   9.7	   67.5	   1.6	   0.15	  
55	   17.7	   84	   3.7	   0.4	  
	  
48	  
	  
32	   1.3	   35	   0.3	   0	  
35.5	   3.95	   50.5	   0.65	   0	  
37	   5.6	   55	   1.4	   0	  
72	  
	  
28	   1.1	   26	   0.2	   0	  
32	   1.55	   36.5	   0.5	   0	  
37	   1.9	   53	   0.7	   0.1	  
96	  
	  
26	   0.9	   10	   0.2	   0	  
30	   0.95	   37	   0.35	   0	  
34	   1	   60	   0.5	   0.2	  
120	  
	  
26	   0.4	   21	   0.2	   0	  
31	   0.6	   28.5	   0.4	   0.05	  
36	   1.4	   44	   0.7	   0.2	  
Total	  
	  
26	   0.55	   16	   0.25	   0	  
32	   1.25	   39.5	   0.4	   0	  
38.5	   2.3	   62	   1	   0.2	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8.2 Data for Chapter 5 
 
Table A4. Raw data after repeated through-and-through joint lavage. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Horse	   Time	  
(h)	  
TP	  
(g/L)	  
NCC	  
(x109	  
cells/L)	  
Neutrophils	  
(%)	  
Systemic	  SAA	  
(mg/L)	  
Synovial	  
SAA	  (mg/L)	  
H1	   0	   17	   0.1	   1	   0.1	   0	  
H2	   0	   25	   0.5	   64	   0	   0	  
H3	   0	   10	   0.5	   40	   0.6	   0	  
H4	   0	   10	   0.5	   58	   0.2	   0	  
H5	   0	   15	   0.1	   5	   0.2	   0	  
H6	   0	   10	   0.1	   3	   0.1	   0	  
H1	   24	   20	   2.8	   45	   0	   0	  
H2	   24	   28	   8.2	   64	   0.1	   0	  
H3	   24	   39	   18.6	   57	   0	   0	  
H4	   24	   25	   6	   47	   0	   0	  
H5	   24	   37	   19.5	   51	   0	   0	  
H6	   24	   60	   38.4	   67	   0	   0	  
H1	   48	   15	   1.6	   23	   0	   0	  
H2	   48	   30	   2.5	   44	   0	   0	  
H3	   48	   35	   6.3	   63	   0	   0	  
H4	   48	   25	   2.7	   46	   0	   0	  
H5	   48	   26	   5.7	   45	   0	   0	  
H6	   48	   35	   11.3	   58	   0.2	   0	  
H1	   72	   20	   3.5	   58	   0	   0	  
H2	   72	   20	   2.9	   59	   0.1	   0	  
H3	   72	   31	   2.9	   55	   0	   0	  
H4	   72	   22	   11.4	   74	   0	   0	  
H5	   72	   26	   6	   31	   0	   0	  
H6	   72	   40	   7.9	   64	   0	   0	  
H1	   96	   20	   8.6	   75	   0	   0	  
H2	   96	   27	   3.6	   59	   0	   0	  
H3	   96	   25	   1.8	   37	   0	   0	  
H4	   96	   20	   3.5	   56	   0	   0	  
H5	   96	   23	   2.3	   21	   0	   0	  
H6	   96	   35	   3.2	   47	   0	   0	  
H1	   120	   25	   2.7	   52	   0.1	   0	  
H2	   120	   29	   2.8	   78	   0	   0	  
H3	   120	   26	   3.2	   71	   0	   0	  
H4	   120	   25	   14.3	   72	   0	   0	  
H5	   120	   29	   6.1	   42	   0	   0	  
H6	   120	   37	   6.1	   56	   0.2	   0	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Table A5. Raw data blood contamination and needle repositioning 
 
Horse	   Blood	  Contamination	  
Needle	  
Replacement	  
H1	   0	   2	  
H2	   4	   3	  
H3	   4	   1	  
H4	   2	   2	  
H5	   1	   0	  
H6	   0	   0	  
H1	   2	   0	  
H2	   4	   0	  
H3	   3	   0	  
H4	   4	   0	  
H5	   3	   0	  
H6	   4	   0	  
H1	   2	   2	  
H2	   4	   0	  
H3	   3	   0	  
H4	   3	   2	  
H5	   2	   0	  
H6	   4	   1	  
H1	   2	   0	  
H2	   2	   0	  
H3	   3	   0	  
H4	   3	   0	  
H5	   0	   0	  
H6	   4	   0	  
H1	   4	   0	  
H2	   2	   0	  
H3	   2	   2	  
H4	   3	   0	  
H5	   3	   1	  
H6	   3	   0	  
H1	   2	   0	  
H2	   3	   0	  
H3	   2	   0	  
H4	   3	   0	  
H5	   2	   0	  
H6	   2	   0	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Table A6. Summary statistics after repeated through-and-through joint lavage: p25, p50 
(median) and p75; by time. 
 
Time	  
(h)	  
TP	  
(g/L)	  
NCC	  
(x109	  cells/L)	  
Neutrophils	  
(%)	  
Systemic	  SAA	  
(mg/L)	  
Synovial	  SAA	  
(mg/L)	  
0	  
	  
10	   0.1	   3	   0.1	   0	  
12.5	   0.3	   22.5	   0.15	   0	  
17	   0.5	   58	   0.2	   0	  
24	  
	  
25	   6	   47	   0	   0	  
32.5	   13.4	   54	   0	   0	  
39	   19.5	   64	   0	   0	  
48	  
	  
25	   2.5	   44	   0	   0	  
28	   4.2	   45.5	   0	   0	  
35	   6.3	   58	   0	   0	  
72	  
	  
20	   2.9	   55	   0	   0	  
24	   4.75	   58.5	   0	   0	  
31	   7.9	   64	   0	   0	  
96	  
	  
20	   2.3	   37	   0	   0	  
24	   3.35	   51.5	   0	   0	  
27	   3.6	   59	   0	   0	  
120	  
	  
25	   2.8	   52	   0	   0	  
27.5	   4.65	   63.5	   0	   0	  
29	   6.1	   72	   0.1	   0	  
Total	  
	  
20	   2.4	   43	   0	   0	  
25	   3.35	   55.5	   0	   0	  
30.5	   7.1	   63.5	   0.1	   0	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8.3 Animal Care Certificate of Approval for experimental study of Chapter 4 
 
 
 
 
 
 
Please send all correspondence to:   Research Ethics Office 
 University of Saskatchewan 
 Box 5000 RPO University, 1607-110 Gymnasium Place 
 Saskatoon SK  S7N 4J8 
 Telephone: (306) 966-7928     Fax: (306) 966-2069      Email: ucacs.office@usask.ca  
Animal Research Ethics Board (AREB)  
 Certificate of Approval 
 
RPRINCIPAL INVESTIGATOR DEPARTMENT/ORGANIZATION ANIMAL USE PROTOCOL # 
Dr. Joe Bracamonte  Large Animal Clinical Sciences  20130044  
 
 
TITLE 
Evaluation of the effect of arthroscopic lavage on serum amyloid A concentration, total protein and nucleated cell count in 
synovial fluid of healthy horses. 
 
  
SPONSORING AGENCIES 
University of Saskatchewan WCVM Equine Health Research Fund 
 
 
BIOSAFETY NUMBER      UNIFI FUND # 
R-LAC-12        
 
 
APPROVAL DATE:  APPROVAL OF: EXPIRY DATE: 
May 7, 2013 New Animal Use Protocol April 30, 2014  
 
 
Full Board Meeting       AREB Subcommittee      AREB Chair and                 AREB Chair       
     University Veterinarian 
 
 
 
CERTIFICATION 
The University of Saskatchewan Animal Research Ethics Board reviewed the above-named research project.  The 
proposal was found to be acceptable on ethical grounds.  The principal investigator has the responsibility for any other 
administrative or regulatory approvals that may pertain to this research project, and for ensuring that the authorized 
research is carried out according to the conditions outlined in the original protocol submitted for ethics review. This 
Certificate of Approval is valid for the above time period.  
 
PROTOCOL MODIFICATIONS 
Any modifications to this protocol must be approved by the UCACS AREB Chair prior to implementation, using the AUP 
Modification Form.   
 
ONGOING REVIEW REQUIREMENTS 
Research programs that extend beyond one year must receive annual review.  For the annual renewal, an annual review 
form (and progress report) must be submitted to the AREB within one month of the current expiry date each year the 
study remains open, and upon study completion.  Please refer to the Research Ethics Office website for further 
instructions. 
 
 
 
 
  May 14, 2013  
Michael Corcoran, Chair  Date Issued  
Animal Research Ethics Board 
University of Saskatchewan 
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8.4 Animal Care Certificate of Approval for experimental study of Chapter 5 
 
 
 
 
Animal Research Ethics Board 
  
 
Certificate of Approval 
 
RPRINCIPAL INVESTIGATOR DEPARTMENT/ORGANIZATION ANIMAL USE PROTOCOL # 
Dr. Joe Bracamonte  Large Animal Clinical Sciences  20140010  
 
 
TITLE 
Evaluation of the effect of through-and-through joint lavage on serum amyloid A concentration, total protein and nucleated 
cell count in synovial fluid of healthy horses 
 
  
SPONSORING AGENCIES 
University of Saskatchewan - WCVM Equine Health Research Fund 
 
 
BIOSAFETY NUMBER      UNIFI FUND # 
R-LAC-12        
 
 
APPROVAL DATE:  APPROVAL OF: EXPIRY DATE: 
March 19, 2014 New Animal Use Protocol March 31, 2015  
 
 
Full Board Meeting       AREB Subcommittee        AREB Chair and                 AREB Chair       
     University Veterinarian 
 
 
 
CERTIFICATION 
The University of Saskatchewan Animal Research Ethics Board reviewed the above-named research project.  The 
proposal was found to be acceptable on ethical grounds.  The principal investigator has the responsibility for any other 
administrative or regulatory approvals that may pertain to this research project, and for ensuring that the authorized 
research is carried out according to the conditions outlined in the original protocol submitted for ethics review. This 
Certificate of Approval is valid for the above time period.  
 
PROTOCOL MODIFICATIONS 
Any modifications to this protocol must be approved by the UCACS AREB Chair prior to implementation, using the AUP 
Modification Form.   
 
ONGOING REVIEW REQUIREMENTS 
Research programs that extend beyond one year must receive annual review.  For the annual renewal, an annual review 
form (and progress report) must be submitted to the AREB within one month of the current expiry date each year the 
study remains open, and upon study completion.  Please refer to the Research Ethics Office website for further 
instructions. 
 
 
 
 
  March 20, 2014  
Michael Corcoran, Chair  Date Issued  
Animal Research Ethics Board 
University of Saskatchewan 
 
 
 
Please send all correspondence to:   Research Ethics Office 
 University of Saskatchewan 
 Box 5000 RPO University, 1607-110 Gymnasium Place 
 Saskatoon SK  S7N 4J8 
 Telephone: (306) 966-7928     Fax: (306) 966-2069      Email: ucacs.office@usask.ca  
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CHAPTER 9: VITA 
 
Dr. Andrés Sanchez Teran is originally from Quito, Ecuador. In the year of 2000 after 
graduating from the American School of Quito he was accepted to the Facultad de Medicina 
Veterinaria y Zootecnia of the Universidad Central del Ecuador to study Veterinary Medicine. 
Dr. Sanchez Teran was interested in specializing in large animal and after completing his 3rd year 
of veterinary medicine in Ecuador, he decided to transfer to the Facultad de Ciencias 
Veterinarias of the Universidad Nacional del Centro de la Provincia de Buenos Aires in 
Argentina where he completed his Veterinary degree in 2009. During his last year of studies he 
was awarded a scholarship to visit the Veterinary Teaching Hospital of the University of 
Tennessee. There he focused on pursuing the path to become a board certified surgeon by the 
American College of Veterinary Surgeons (ACVS). Also, during his last two years of studies he 
served as a research assistant student at the Pharmacology Department where he gained a strong 
interest as a researcher. After graduating as a Veterinarian, he worked in two renamed 
Thoroughbred breeding farms in Argentina where he continued affirming his profound interest in 
equine surgery. 
In 2010 he decided to go back to his home country, Ecuador while applying for an 
internship. He began a one-year Internship in Equine Surgery and Medicine at the Onderstepoort 
Veterinary Academic Hospital of the University of Pretoria, South Africa in March 2011. During 
his internship he also completed a degree of Master of Science in Veterinary Sciences with 
distinction and under the direct supervision of Prof. Luis Rubio-Martínez. After his internship, he 
was accepted at the Western College of Veterinary Medicine, University of Saskatchewan in July 
2012 to complete a 3-year Large Animal Surgery Residency program together with a Master of 
Science degree under the direct supervision of Dr. Joe Bracamonte. This thesis serves as a partial 
fulfillment for the requirements to obtain the latter degree. Dr. Sanchez Teran is currently on his 
last weeks of clinical training as large animal surgeon and will be taking his board exams for the 
ACVS in February 2016. 
 
 
